On the cover:
Top row (left to right): Elizabeth M. Jaffee, MD, FAACR, 2018-2019 AACR President; Chuck Dandridge (second from right), an acute myeloid leukemia survivor featured in the AACR Cancer Progress Report 2018; Michael A. Caligiuri, MD, FAACR, 2017-2018 AACR President; Tori Lee (center), a leukemia survivor featured in the AACR Cancer Progress Report 2018. DRIVING INNOVATIVE
Middle row (left to right): Margaret Foti, AACR Chief Executive Officer; Laurie Trotman, a breast cancer survivor featured in the AACR Cancer CANCER SCIENCE Progress Report 2018. TO PATIENT CARE Bottom row (left to right): Lucile L. Adams-Campbell, PhD, Chair of the AACR Women in Cancer Research Council; Mike Delia, a non-Hodgkin lymphoma survivor featured in the AACR Cancer Progress Report 2018; James P. Allison, PhD, FAACR, a former member of the AACR Board of Directors who received the Nobel Prize in Physiology or Medicine in 2018 for his shared discovery of cancer therapy by inhibition of negative immune regulation; Ron Scolamiero (left), a prostate cancer survivor featured in the AACR Cancer Progress Report 2018.
AACR.org/AnnualReport18 AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL REPORT
1810051_AACR2018AnnRepCOV_11x8.5_2.indd All Pages 6/3/19 12:04 PM AACR.org • Follow us: blog.aacr.orgDONATE
WELCOME: DRIVING INNOVATIVE CONTENTS CANCER SCIENCE TO PATIENT CARE 2
PROGRESS AGAINST CANCER IN 2018 4
AACR ANNUAL MEETING 2018 8
SCIENTIFIC PUBLISHING 16 2 4 8 AACR INTERNATIONAL 22
HONORING SCIENTIFIC ACHIEVEMENT 26
SCIENCE AND EDUCATION 34
SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION 46
16 22 26 34 POLICY AND ADVOCACY 54
54 62 68 MEMBERSHIP 62
LEADERSHIP 68 46 AACR FOUNDATION 78
FINANCIAL STATEMENT 90
78 90 92 THE AACR IN 2019: A LOOK AHEAD 92
American Association for Cancer Research Annual Report 2018 I 1
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 2-1 6/3/19 11:30 AM WELCOME
DRIVING INNOVATIVE CANCER SCIENCE TO PATIENT CARE
Dear Colleagues The theme of the AACR Annual Meeting of cancer treatment—and celebrated a Conference is an example of the AACR’s 2018, “Driving Innovative Cancer Science major accomplishment by one of our most global collaboration to advance cancer and Friends: to Patient Care,” is also the theme of this distinguished members. AACR member science. AACR conferences such as this one report. The report outlines all the ways and Fellow of the AACR Academy James bring together the greatest minds in cancer in which AACR programs and initiatives P. Allison, PhD, FAACR—along with his research to share the latest developments We are pleased to present support the efforts of investigators from the colleague, Tasuku Honjo, MD, PhD—was in the field, and special conferences—such the 2018 Annual Report of laboratory to the clinic to improve the lives awarded the Nobel Prize in Physiology as the AACR’s first conference on Tumor of cancer patients. or Medicine in October for his shared Immunology in 2006—identify promising the American Association discovery of cancer therapy by inhibition areas of inquiry and inspire scientists As the report documents, 2018 was a of negative immune regulation. The day to pursue new approaches. And AACR for Cancer Research (AACR). spectacular year for the AACR, one that after the announcement, we were fortunate grants and scientific achievement awards The report highlights the was marked by several milestones. The to have Dr. Allison attend the Fourth CRI- identify promising young investigators and AACR Annual Meeting attracted a record CIMT-EATI-AACR International Cancer accomplished senior scientists—including AACR’s progress over the number of participants, as we welcomed Immunotherapy Conference: Translating Dr. Allison in 2013, 2014, and 2015 (see past year in support of our more than 22,500 scientists, clinicians, Science into Survival. As he entered the p. 30)—and support their efforts to find the other health care professionals, survivors, ballroom for the morning session at the next breakthrough. mission: to prevent and cure and advocates to Chicago to share the conference, Dr. Allison received a standing latest breakthroughs in cancer science. The ovation from his friends, his colleagues, and Continued progress against cancer requires cancer through research, organization expanded its global outreach, the other senior investigators and early- continued inspiration and innovation. As education, communication, collaborating with 16 different international career scientists in attendance. outlined in this report, the AACR meets scientific organizations to foster progress the challenge of driving innovative cancer collaboration, funding, and against cancer around the world. And It is fitting that Dr. Allison was at an AACR science to patient care by pursuing an advocacy. AACR Project GENIE (Genomics Evidence conference to celebrate the breakthroughs agenda that is scientifically bold, broad, and Neoplasia Information Exchange) doubled that led to his recognition by the Nobel collaborative. Powered by the dedicated in size, welcoming 11 new participating committee, as the AACR is uniquely efforts of our 42,000 members, and guided institutions that are committed to its goal positioned to support such breakthroughs by the best minds in cancer research, the of delivering the benefits of precision in all areas of cancer research. As a joint AACR will continue translating knowledge medicine to cancer patients. effort with the Cancer Research Institute into breakthroughs until our mission—the (CRI), the Association for Cancer prevention and cure of all cancers—is In addition to these achievements, in 2018 Immunotherapy (CIMT), and the European realized. we witnessed the confirmation of the place Academy of Tumor Immunology (EATI), of cancer immunotherapy among the pillars the International Cancer Immunotherapy
MARGARET FOTI, PHD, MD (HC) ELIZABETH M. JAFFEE, MD, FAACR MICHAEL A. CALIGIURI, MD, FAACR AACR Chief Executive Officer AACR President 2018-2019 AACR President 2017-2018 2 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 3
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 2-3 6/3/19 11:30 AM PROGRESS AGAINST CANCER 2018 PROGRESS DRIVEN BY RESEARCH AGAINST
Research discoveries providing deep insights into the complexities of cancer CANCER 90 are driving vital progress in public 80 health and spurring the development IN 2018 70 of lifesaving improvements across the cancer care spectrum. Research-fueled 60 advances in 2018 include the 18 new 50 therapeutics approved by the U.S. Food 40
and Drug Administration (FDA) for 30
treating patients with various types of 20
cancer. During this time period, the FDA 10 also approved 10 previously approved NUMBER OF NEW ANTICANCER
THERAPEUTICS APPROVED BY THE FDA BY THERAPEUTICS APPROVED 0 anticancer therapeutics for treating new 1999-2008 2009-2018 types of cancer. The pace at which research discoveries are being converted to new anticancer therapeutics has been accelerating in recent years, as illustrated by the fact that the number of new anticancer therapeutics approved by the Food and Drug Administration (FDA) from 2009 to 2018 (yellow bar) was more than double the number approved by the agency in the previous decade (1999- 2008; blue bar). Adapted from the AACR Cancer Progress Report 2018 (Fig. 9).
A featured survivor in the AACR Cancer Progress Report 2018, Ron Scolamiero (with his wife, Laurie) participated in a clinical trial of apalutamide, a new molecularly targeted therapeutic, to treat his prostate cancer. He is currently cancer free. Apalutamide was approved for patients with non-metastatic castration-resistant prostate cancer in 2018.
4 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 5
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 4-5 6/3/19 11:30 AM PROGRESS AGAINST CANCER 2018
One of the areas of cancer treatment Another two anticancer therapeutics to in which researchers are making gain FDA approvals in 2018 are providing extraordinarily rapid progress is oncologists with an exciting new way to use immunotherapy, which refers to the use radiotherapy to treat neuroendocrine tumors. of therapeutics that harness the power of These pioneering targeted radiotherapeutics “ Enlisting experts from an NICOLE DICAMILLO CANCER SURVIVOR a patient’s own immune system to treat are benefiting many patients, including Nicole his or her cancer. These revolutionary DiCamillo (far left). even broader spectrum of anticancer therapeutics include seven of the therapeutics to gain FDA approvals in 2018. The AACR is proud to have helped catalyze disciplines, including physics, Including these approvals, the number of the progress made against cancer in 2018 types of cancer that can be treated by at through its many programs, services, and chemistry, engineering, least one immunotherapeutic has more initiatives. For example, early data from A featured survivor in the AACR Cancer Progress Report 2018, Nicole than tripled in the past decade, increasing one of the trials that led to the November mathematics, and computer DiCamillo was diagnosed with gastroenteropancreatic neuroendocrine from just six to 20. 2018 approval of larotrectinib for treating tumor—a rare type of cancer, which used to be called carcinoid cancer, certain patients with solid tumors that have science, will significantly that can arise in the pancreas or in other parts of the gastrointestinal Discoveries that deepen our understanding a particular type of NTRK gene mutation tract—at the age of 27. For the next 12 years she underwent surgeries, of cancer biology are continuing to catalyze were presented at the AACR Annual accelerate the pace of chemoembolizations, radiofrequency ablations, and other treatments, the development of new therapeutics that Meeting 2016. which kept the cancer at bay but did not control the debilitating symptoms target specific molecules involved in cancer progress in the future. and to expand the use of those agents With the number of cancer cases ” it caused. In 2016, Nicole began a targeted radiation treatment called Lutathera, which delivers a radioisotope directly to the cancer cells after it that have already been approved. These diagnosed in the United States rising every — ELIZABETH M. JAFFEE, MD, FAACR, AACR PRESIDENT (2018-2019) AACR CANCER PROGRESS REPORT 2018 has been infused or injected: anticancer therapeutics are referred to as year, it is vital that the AACR increase molecularly targeted therapeutics. Eighteen public understanding of cancer and the such therapeutics gained FDA approvals importance of cancer research for saving Over the years, I have had many treatments that have controlled the cancer, “ in 2018, including larotrectinib (Vitrakvi), lives. The annual AACR Cancer Progress [but] none stopped the stomach and intestinal issues that greatly reduced which is the first molecularly targeted Report is a cornerstone of these educational my quality of life. Then, in 2016, I started seeing a new doctor and received The AACR Cancer Progress Report 2018 As AACR President (2018–2019) Elizabeth therapeutic to be approved for use based efforts and the AACR’s efforts to advocate four treatments of [the radioisotope] Lutathera through a compassionate achieves these goals by chronicling how M. Jaffee, MD, FAACR, noted in the AACR solely on whether a patient has a tumor for increased annual federal funding by use program. federally funded research discoveries ignited Cancer Progress Report 2018, “Enlisting with certain molecular characteristics government entities that fuel progress progress against cancer over a 12-month experts from an even broader spectrum of rather than where in the body the against cancer and improve public health, Lutathera has changed my life…. Not only is it shrinking the tumors, it is period. The report also highlights that disciplines, including physics, chemistry, tumor originated. Molecularly targeted in particular the National Institutes of allowing me to live a normal life with my husband and kids. I never take unwavering, bipartisan support from engineering, mathematics, and computer therapeutics are part of the precision Health (NIH), National Cancer Institute days off work. I coach my son’s soccer team. I watch my kids’ concerts. I Congress, in the form of robust, sustained, science, will significantly accelerate the pace medicine revolution that is ensuring (NCI), FDA, and Centers for Disease couldn’t even have dreamed of doing these things before Lutathera. It is the and predictable annual increases in funding of progress in the future.” that more and more people live longer, Control and Prevention (CDC). best thing that has happened for me and for my family.” for the NIH, NCI, FDA, and CDC, is vital if higher-quality lives after a cancer diagnosis, we are to save more lives from cancer. Learn more about Nicole’s story: AACR.org/Nicole including Ron Scolamiero (p. 5).
6 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 7
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 6-7 6/3/19 11:30 AM ANNUAL MEETING 2018
DRIVING INNOVATION FOR PATIENTS
The AACR Annual Meeting WELCOMING THE NEW DIRECTOR OF THE NATIONAL CANCER INSTITUTE (NCI) sets the research agenda for Six months after being sworn in as the 15th • Big Data. Increase data aggregation and the individuals and institutions director of the NCI, Norman E. Sharpless, interpretation to accelerate research and working across the full MD, FAACR chose the AACR Annual improve patient care. Meeting 2018 as the forum for his first • Clinical Trials. Fully realize the power of spectrum of basic, translational, major public address. Reporting to AACR clinical trials through innovative design, members and other meeting attendees and clinical science to prevent administration, and analyses. on the results of his listening tour of the and cure cancer. For the National Cancer Program, Dr. Sharpless After his address, Dr. Sharpless joined discussed four key areas of focus for the NCI sixth consecutive year, the AACR Immediate Past President Michael that will catalyze progress against cancer: meeting hosted a record A. Caligiuri, MD, FAACR, and AACR • Workforce Training and Development. President Elizabeth M. Jaffee, MD, FAACR, New NCI Director Norman E. Sharpless, MD, FAACR, reports on the results of number of attendees; the Support the cancer research enterprise for a “fireside chat” to discuss the key focus ANNUAL his listening tour of the National Cancer AACR welcomed more than by fostering a diverse and talented cancer areas in more detail and take questions Program and discusses his key areas of workforce. from the audience. focus for the NCI. 22,500 scientists, clinicians, • Basic Science. Reaffirm the NCI’s other health care professionals, commitment to basic science to drive MEETING survivors, patients, and novel approaches and technologies. advocates to Chicago to “PROGRESS AND PROMISE” IN CHICAGO 2018 share and discuss the latest The AACR Annual Meeting brings Moderated by incoming AACR President breakthroughs in cancer together all stakeholders in the cancer Elizabeth M. Jaffee, MD, FAACR, the science. With its expanding research enterprise to share the latest event featured leading experts in cancer advances in cancer research and research discussing the current state of audience and broad scientific treatment; for the third consecutive year, cancer prevention and interception and focus, the Annual Meeting has the AACR brought these advances to the breakthroughs in cancer treatment— local community. The AACR partnered specifically, precision medicine and AACR President (2017-2018) Michael become the forum of choice for with the Chicago Tribune Prime Expo to immunotherapy. The event concluded with A. Caligiuri, MD, FAACR, addresses thought leaders in the cancer present “Progress and Promise against a panel of patient advocates who placed attendees during the opening ceremony Cancer,” an educational event for residents these advances into the context of their own of the AACR Annual Meeting 2018. research community. in the Chicago area. cancer journeys.
8 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 9
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 8-9 6/3/19 11:30 AM ANNUAL MEETING 2018
INNOVATIVE CANCER SCIENCE
The theme of the AACR Annual Meeting 2018, Driving Innovative Cancer Science to Patient Care, emphasized how progress against cancer is driven by discoveries in all areas of cancer research and the cancer-related sciences. The program for the meeting, which featured the latest advances across the cancer research continuum, was developed with the goal of catalyzing Elaine R. Mardis, PhD, 2018-2019 AACR cancer, which have yielded new insights chemotherapy significantly improved targeted therapeutics—and to move these new breakthroughs for patients. President-Elect, discussed key basic into cancer biology and identified potential overall survival, and results from the revolutionary therapeutics to earlier lines of Klaus Pantel, MD, PhD, delivers his presentation on "Liquid biopsy: Novel science research presentations with a focus new combination treatments. Dr. Mardis second trial, CheckMate-227, showed that treatment in a safe and effective way. technologies and clinical applications" at the opening plenary session of the on those showing how new technologies concluded by reminding the audience that patients who received two checkpoint AACR Annual Meeting 2018. Highlights of the cutting-edge research presented at the meeting were summarized by and computational analysis approaches are as technological advances continue to drive inhibitors—nivolumab plus ipilimumab— Elizabeth M. Jaffee, MD, FAACR, AACR experts in a wrap-up plenary session. significantly increasing our understanding progress in basic cancer science, we will had significantly longer progression- AACR President 2018–2019, concluded of cancer. Dr. Mardis, who was also chair see further application of precision cancer free survival compared with those who the session by explaining that despite of the 2018 Annual Meeting Program medicine and better outcomes for patients. received chemotherapy. Dr. Caligiuri then the incredible advances we are making Committee, highlighted presentations highlighted several presentations about against the collection of diseases we call The first presenter, Avrum E. Spira, identify new approaches to prevention and outlining how next-generation sequencing Michael A. Caligiuri, MD, FAACR, clinical trials testing molecularly targeted cancer, they remain a global challenge. MD, MSc, gave an overview of some of early detection. Dr. Spira then discussed is deepening our knowledge of the cancer AACR President 2017–2018, highlighted therapeutics, including the ARROW trial She then highlighted several cutting-edge the cancer prevention, early detection, early promising data from clinical trials genome and epigenome, how liquid biopsies some of the groundbreaking clinical of BLU-667 for RET-altered cancers, areas of research that she believes will and interception research reported at testing immunoprevention approaches in are being used to understand how cancers research presented at the meeting. He the EORTC 90101 trial of crizotinib for ignite quantum leaps forward, including the meeting. He opened by focusing on patients with either colonic polyps or ductal become resistant to treatment over time, began by discussing two potentially ALK-altered inflammatory myofibroblastic convergence science, implementation two presentations about efforts to create carcinoma in situ and studies using liquid and how advanced technologies are being practice-changing phase III clinical tumor, and biomarker data from the and behavioral sciences, and survivorship a precancer atlas similar to The Cancer biopsies for early detection of cancer. Lastly, used to study the molecular characteristics trials testing immunotherapeutics PALOMA-3 trial of palbociclib for HER2- research. She also emphasized the Genome Atlas but in premalignancy Dr. Spira highlighted the challenges facing of individual cells in a tumor—including called checkpoint inhibitors as initial negative breast cancer. Throughout his importance of enhancing support for for squamous cell lung cancer and cancer survivors that were discussed in a cancer cells, immune cells, and other cells treatment for metastatic non–small cell presentation, Dr. Caligiuri emphasized early- and mid-career cancer researchers, multiple myeloma. He explained that the special cancer survivorship session held in in the tumor microenvironment. She also lung cancer. Results from the first trial, how identifying biomarkers of response in particular female and minority cancer information gained from these studies memory of Fellow of the AACR Academy summarized two presentations on the use KEYNOTE-189, showed that adding the is essential if we are to optimize the use researchers, in order to accelerate the pace about the earliest cellular and molecular Jimmie C. Holland, MD, FAACR. of systems biology approaches to model checkpoint inhibitor pembrolizumab to of immunotherapeutics and molecularly of scientific and clinical progress. events leading to invasive cancer could
10 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 11
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 10-11 6/3/19 11:30 AM ANNUAL MEETING 2018
AT A GLANCE
sessions brought together experts to address free survival compared with patients 22,500 some of the major challenges in cancer 167 who received the standard-of-care People attended the meeting. The Annual research, such as the problem of cancer Clinical trials were presented, the largest chemotherapy. These data could establish Meeting 2018 was the largest in the history cachexia, the failure to translate IGF-1R and number of trials ever presented at an AACR the combination of nivolumab plus of the AACR. PI3K inhibitors into effective treatments, Annual Meeting. Several high-impact ipilimumab as a first-line treatment option and how the age of patients at the time of trials were presented in special sessions, for patients with high-TMB NSCLC. cancer diagnosis impacts cancer genomics including two trials that received significant 69 and drug development. media coverage for their practice-changing Countries were represented at the meeting. results that demonstrate the potential of 33 cancer immunotherapy: Recent Advances sessions were presented at 7 the meeting to provide attendees with the • According to data from the phase III 6,328 Panelists participated in a special session latest updates in critical areas of research. trial KEYNOTE-189, treatment with Proffered papers were accepted for titled “The Cancer Survivorship Landscape: In addition to sessions on organ sites, pembrolizumab in combination with presentation in poster sessions or Potential Focus Areas for the Future.” diagnostics and therapeutics, and cancer chemotherapy improved the overall minisymposia. A total of 27 of these papers Chaired by Anna D. Barker, PhD, the prevention, the program featured sessions response rate in patients with metastatic were selected for presentation in poster session was presented in memory of on Recent Advances in Cancer Health nonsquamous non-small cell lung cancer, discussion sessions; this new type of session Jimmie C. Holland, MD, FAACR, a 20-year Disparities Research. These sessions—which reducing by half the risk of death for provided the presenters of highly-rated AACR member and pioneer in the field of were added to the program by 2017-2018 previously untreated patients. These posters with an opportunity to share their psycho-oncology who died in December AACR President Michael A. Caligiuri, results set the stage for pembrolizumab to work in a brief oral presentation. 2017. The panelists represented the entire MD, FAACR, as part of his presidential become a standard treatment for patients continuum from cancer research to cancer initiative to highlight the issue of cancer with non–small cell lung cancer (NSCLC). care and patient advocacy, and they health disparities—focused on the scientific 253 addressed several issues affecting cancer • Results from another phase III trial questions that must be answered to ensure Scientific sessions highlighted the latest survivors, including the psychosocial and (CheckMate-227) demonstrated that, that all patients benefit from breakthroughs in innovative basic, translational, and lifestyle aspects of cancer survivorship; among patients newly diagnosed with in cancer treatment regardless of race or Leena Gandhi, MD, PhD, presents clinical cancer science—including 44 major concerns regarding the development of advanced NSCLC with high tumor socioeconomic status. the results of the phase III trial symposia, five plenary sessions, and 47 second malignancies; and challenges such mutational burden (TMB), those who KEYNOTE-189 in a clinical trials educational sessions. The program included as comorbidities and the toxicities resulting received nivolumab plus ipilimumab plenary session at the AACR Annual Meeting 2018. three “Unsolved Mysteries” sessions; these from current and prior treatments. had significantly improved progression-
12 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 13
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 12-13 6/3/19 11:30 AM ANNUAL MEETING 2018
FACEBOOK LIVE BROADCAST AMONG THE MANY NEWS ORGANIZATIONS COVERING MEDIA COVERAGE THE ANNUAL MEETING WERE THE FOLLOWING MAJOR MEDIA OUTLETS: The AACR Annual Meeting 2018 generated global interest, as the innovative cancer science presented in Washington produced a significant amount of news coverage and social media activity.
33 40,482 News releases were distributed. Tweets mentioned the #AACR18 hashtag. 185 10,324 Reporters registered to cover the meeting. Unique users joined the Annual Meeting conversation on Twitter. @AACRPRES 2,666 ON TWITTER Media mentions were generated. 500 Number of followers for the @AACRPres Twitter account. The AACR launched the 21,592 social media account during the Annual People viewed the AACR’s Facebook Live Business Meeting of Members, when broadcasts during the Annual Meeting. Elizabeth M. Jaffee, MD, FAACR, began The AACR conducted seven live broadcasts her term as President. The account offers during the meeting, including a discussion of followers a perspective on the unique important science presented at the meeting. experience of serving as President of 2017-2018 AACR President Michael A. the AACR. Caligiuri, MD, FAACR, hosted the broadcast, which featured Annual Meeting Program Chair Elaine R. Mardis, PhD.
Reporters learned about the latest developments in cancer research at three press conferences during the AACR Annual Meeting 2018.
14 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 15
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 14-15 6/3/19 11:30 AM SCIENTIFIC PUBLISHING
Authors of the most cited articles published in AACR journals in 2016 SCIENTIFIC were recognized during a reception at the AACR Annual Meeting 2018. PUBLISHING AACR JOURNALS: PUBLISHING HIGH-IMPACT CANCER SCIENCE
The eight journals in the NEW EDITORIAL LEADERSHIP FOR CANCER RESEARCH AACR’s scientific publishing In January 2018, Chi Van Dang, MD, PhD, program represent four began his appointment as the new editor- in-chief of Cancer Research, the AACR’s percent of all journals in longest-running journal. Dr. Dang—whose the oncology field, but they work has significantly contributed to the understanding of molecular signaling garner 15 percent of all pathways and mechanisms that govern the unusual metabolism of cancer cells— citations in that field (Journal currently serves as Scientific Director of the Citation Report®, 2018). This Ludwig Institute for Cancer Research.
impact on the field—which The second-most frequently cited cancer is due in large part to the journal in the world, Cancer Research publishes high-impact papers in all areas vision of their editors-in- of cancer science. The cancer field changes chief and the expertise rapidly, and in his first year Dr. Dang has launched new sections of the journal to of their editorial boards— reflect those changes. By inviting engineers, Chi Van Dang, MD, PhD, new editor-in-chief of Cancer Research, discusses the mathematicians, physicists, and data marks AACR journals as journal at a Meet the Editor session during the AACR Annual Meeting. scientists to share their work in Cancer publication venues of choice Research, and by introducing to the cancer research community emerging tools and across the spectrum of technologies to attack the cancer problem, basic, translational, clinical, Dr. Dang has enhanced the journal’s position as a critical driver of progress and epidemiological cancer against cancer. research.
16 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 17
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 16-17 6/3/19 11:30 AM SCIENTIFIC PUBLISHING
Cancer ACKNOWLEDGING Molecular Cancer Epidemiology, Cancer OUTSTANDING EDITORIAL Therapeutics Biomarkers Prevention SERVICE (MCT) & Prevention Research The AACR gratefully acknowledges the Napoleone (CEBP) Scott M. contributions of three editors-in-chief Ferrara, MD, Timothy R. Lippman, MD whose terms of service ended in 2018: FAACR Rebbeck, PhD
Since his appointment as editor-in-chief began in cancer sites using data compiled by the International As the founding editor-in-chief, Scott • A randomized, placebo-controlled In his inaugural editorial as editor-in- discovery and preclinical development during 2008, Timothy R. Rebbeck, PhD, has positioned Agency for Research on Cancer (IARC). Lippman, MD, established Cancer phase II trial of the oral prostacyclin chief, Napoleone Ferrara, MD, FAACR, Dr. Ferrara’s tenure, including the following CEBP as a critical cross-disciplinary publication [Jemal et al., August 2010] Prevention Research as the first scientific analogue iloprost, which showed an noted that despite the great progress made highly-cited articles: in cancer treatment, more than 90% of venue for a range of interdependent fields, including journal devoted exclusively to cancer improvement in bronchial histology • A review of PD-L1 IHC as a predictive • A study demonstrating the expression of PD-1 phase III clinical trials in oncology still epidemiology, translational science, survivorship, prevention. In addition to providing a in former smokers with sputum biomarker for anti–PD-1/PD-L1 therapy and PD-L1—two potentially targetable immune fail to meet their primary endpoints—a and prevention. During his tenure, Dr. Rebbeck critical bridge between basic and clinical atypia—the first and only positive across multiple tumor types. checkpoint proteins—in a substantial proportion of reminder of the ongoing need to improve emphasized the importance of population science prevention research, Dr. Lippman’s vision chemoprevention trial for lung cancer. [Patel et al., April 2015] solid tumors, including some aggressive subtypes the safety and efficacy of new drugs, the for the journal included creating a forum [Keith et al., June 2011] and shaped the journal’s content via commissioned that lack targeted treatment modalities. predictability of preclinical and early- • A detailed study of EPZ-6438, an EZH2 for emerging science that attempted to articles that addressed high-priority issues, including [Gatalica et al., December, 2014] • The first study to demonstrate a durable stage clinical studies, and strategies for inhibitor (in phase I trials at the time) that genetic epidemiology, emerging technologies, extend the current conceptual and practical antibody response from a single dose clinical drug development. During his resulted in profound and durable tumor • The first study to project cancer prevalence in the regression. survivorship, and surveillance. In addition, he boundaries of prevention. His focus of HPV vaccine. Several international tenure, he transformed MCT to address U.S. through 2040 in an aging context, predicting a these challenges, expanding the journal’s [Knutson et al., April 2014] increased the journal’s focus on the full range on cutting-edge science—coupled with trials are underway to investigate the “silver tsunami” in which 73 percent of U.S. cancer focus in critical areas such as biomarkers of health disparities research, to ensure that all an awareness of changes in the current study’s implication that that one dose • A characterization of CB-839, a newly- survivors in 2040 will be 65 or older. and companion diagnostics as well as new patients—including minorities and medically paradigm—established Cancer Prevention of the HPV vaccine may be sufficient— discovered glutaminase inhibitor that may [Bluethmann et al., July 2016] models and technologies. Dr. Ferrara also have therapeutic benefit for patients with underserved populations—benefit from advances in Research as the preferred publication outlet which could have a major impact on expanded the number of high-quality triple-negative breast cancer and perhaps cancer screening and treatment. • An introduction to the OncoArray, an inexpensive for groundbreaking studies, including: implementation science. reviews in the journal with the launch of other glutamine-dependent cancers. genotyping microarray developed by a worldwide • The first prospective assessment of [The CVT Group, November 2013] MCT Focus issues; under his stewardship, CEBP published high-impact research across a [Gross et al., April 2014] community of investigators to understand common confirmed HPV status in black versus the citation impact of review articles wide range of fields under Dr. Rebbeck’s leadership, causes of cancer susceptibility and progression. white head and neck cancer patients, published in MCT increased by 60%. • A study demonstrating that the long noncoding RNA ANRIL promotes including the following highly-cited articles: [Amos et al., January 2017] investigating racial survival disparities in proliferation of non-small cell lung cancer • A review describing the changing global patterns of the HPV-induced cancer epidemic. MCT published high-priority research across the spectrum of oncology drug and inhibits apoptosis. cancer incidence and mortality for select common [Settle and Cullen et al., September 2009] [Nie et al., January 2015]
18 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 19
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 18-19 6/3/19 11:30 AM SCIENTIFIC PUBLISHING
BY THE NUMBERS EDITORS-IN-CHIEF CANCER PREVENTION RESEARCH The AACR thanks its editors-in-chief for their hard work SCOTT M. LIPPMAN, MD UC San Diego Moores Cancer Center San Diego, California 24.373 and stewardship of its scientific publishing program [Until July 2018] Current Impact Factor for Cancer during 2018. Discovery—which ranks sixth out of 222 journals in the Oncology category— according to the 2017 Journal Citation Report. CANCER DISCOVERY CANCER RESEARCH CHI VAN DANG, MD, PHD, FAACR LEWIS C. CANTLEY, PHD, FAACR Ludwig Institute for Cancer Research Sandra and Edward Meyer Cancer Center at New York, New York 4 Weill Cornell Medical College The Wistar Institute New York, New York AACR journals ranked in the top 8% in Philadelphia, Pennsylvania the Oncology category with regard to Impact Factor, according to the Journal JOSÉ BASELGA, MD, PHD, FAACR Memorial Sloan Kettering Cancer Center Citation Report released in July 2018. New York, New York CLINICAL CANCER RESEARCH Cancer Discovery ranked 6th out of all [Until December 2018] KEITH T. FLAHERTY, MD oncology journals, followed by Clinical Massachusetts General Hospital Cancer Center Cancer Research (12th), Cancer Immunology Boston, Massachusetts Research (16th), and Cancer Research (17th). CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION
TIMOTHY R. REBBECK, PHD 35 Dana-Farber Cancer Institute Boston, Massachusetts Days from manuscript submission to first [Until December 2018] MOLECULAR CANCER RESEARCH decision (on average). The AACR has made KAREN E. KNUDSEN, PHD a concerted effort to reduce turnaround Kimmel Cancer Center times for peer review and to improve the Philadelphia, Pennsylvania overall author experience. CANCER IMMUNOLOGY RESEARCH
ROBERT D. SCHREIBER, PHD 26 million Washington University School of Medicine St. Louis, Missouri Full-text views of AACR journal articles were MOLECULAR CANCER THERAPEUTICS recorded in 2018. NAPOLEONE FERRARA, MD, FAACR UC San Diego Moores Cancer Center PHILIP D. GREENBERG, MD San Diego, California Fred Hutchinson Cancer Research Center [Until December 2018] Seattle, Washington
20 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 21
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 20-21 6/3/19 11:30 AM AACR INTERNATIONAL AACR COLLABORATIONS ADVANCING CANCER SCIENCE WORLDWIDE INTERNATIONAL
With programs in 12 countries and members in 120 countries, the AACR collaborates on a global scale to promote scientific excellence and benefit all people by reducing cancer incidence, morbidity, and mortality. Through collaborations with 16 international organizations, the AACR provided scientific conferences, educational workshops, and financial support to the cancer research community on six continents in 2018.
The AACR and the Korean Cancer Association (KCA) collaborated to host the AACR-KCA Joint Conference on Precision Medicine in Solid Tumors. Held in November, the conference was the first AACR-KCA joint program presented in Seoul, Korea.
(Opposite page) AACR President (2017-2018) Michael A. Caligiuri, MD, FAACR, and Cancer Research UK (CRUK) Chief Clinician Charles Swanton, MD, PhD, FRCP, announce a new international alliance between the AACR and CRUK during the opening ceremony of the AACR Annual Meeting 2018.
22 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 23
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 22-23 6/3/19 11:30 AM AACR INTERNATIONAL
SIXTH JCA-AACR SPECIAL JOINT LAUNCHING A NEW CONFERENCE ON THE LATEST ADVANCES TRANSATLANTIC IN LUNG CANCER RESEARCH: FROM BASIC PARTNERSHIP SCIENCE TO THERAPEUTICS Kyoto, Japan, July 2018 In April 2018, the AACR and Cancer Research UK (CRUK) announced a ACORD: AUSTRALIA & ASIA PACIFIC new international alliance aimed toward CLINICAL ONCOLOGY RESEARCH DEVELOPMENT WORKSHOP accelerating the pace of progress against Sydney, Australia, September 2018 cancer. The announcement was made jointly by AACR President (2017-2018) Michael A. SECOND AACR INTERNATIONAL OTHER INTERNATIONAL ESMO ASIA CONGRESS 2018 POSTER PRIZES AND AACR Annual Meeting. Award recipients the AACR Annual Meeting 2018 and WORLD CANCER Caligiuri, MD, FAACR, and CRUK Chief CONFERENCE ON TRANSLATIONAL Singapore, November 2018 CANCER MEDICINE: CANCER DISCOVERIES COLLABORATIONS TRAVEL AWARDS who attended the Annual Meeting provided them with travel support to RESEARCH DAY Clinician Charles Swanton, MD, PhD, FOR CLINICAL APPLICATION The AACR collaborated with the conference 2018 received additional networking attend and present their work at the The AACR worked with additional In 2018, the AACR offered an expanded The AACR joined ten other cofounding FRCP, during the opening ceremony at the organizers to develop two joint symposia: opportunities at the University of Chicago CSCO 21st Annual Meeting (Xiamen, Held in cooperation with LACOG organizations while developing joint slate of opportunities to international partner organizations to mark World Cancer AACR Annual Meeting 2018. São Paulo, Brazil, September 2018 “PD1/PDL1: From Discovery to Clinical provided by the AACR. Hosted by China, September 2018). sessions for the following international investigators to travel to Chicago, Illinois, Research Day on September 24. The goal Use” and “ALK Gene Fusions: From AACR International Affairs Committee conferences: and participate in the AACR Annual of World Cancer Research Day was to raise The alliance between the world’s largest FOURTH CRI-CIMT-EATI-AACR Discovery to Clinical Use.” member Olufunmilayo I. Olopade, INTERNATIONAL CANCER Meeting—the touchstone event for the ENHANCING THE AACR’S awareness of the extraordinary impact of professional organization dedicated to MD, FAACR, the recipients toured the IMMUNOTHERAPY CONFERENCE: A.C. CAMARGO NEXT FRONTIERS TO CURE global cancer research community—while RELATIONSHIP WITH ISRAEL cancer science and to acknowledge the advancing cancer research and the world’s TRANSLATING SCIENCE INTO SURVIVAL CANCER CONFERENCE university hospital and the Olopade INTERNATIONAL AACR also offering opportunities for AACR contributions made by cancer researchers to largest fundraising medical research charity New York, New York, September 2018 São Paolo, Brazil, May 2018 Laboratory, participated in a professional COLLABORATORS IN 2018 members to present their work abroad: While in Jerusalem in October to attend reduce the global burden of cancer. will build transatlantic collaborations The AACR partnered with LACOG to offer development panel with university faculty, the conference on “The Cutting Edge of by establishing training and exchange EACR-AACR-ISCR CONFERENCE: THE • Working with the program committees CUTTING EDGE OF CONTEMPORARY a session on “Science behind the Trial,” in A.C. Camargo Cancer Center and attended the E. E. Just Lecture— Contemporary Cancer Research”—a joint programs, convening international meetings CANCER RESEARCH which Brazilian investigators presented Association for Cancer Immunotherapy (CIMT) for the Frontiers in Cancer Science which honors Ernest Everett Just, one of venture between the AACR, the European and workshops, and uniting the community Jerusalem, Israel, October 2018 the results of three clinical trials and Cancer Science Institute of Singapore (CSI) Conference (Singapore, November 2017; the first African Americans to earn a PhD Association for Cancer Research (EACR), to influence global research policy. AACR scientists discussed the biological Chinese Society for Clinical Oncology (CSCO) organized by the Cancer Science Institute from the university. The recipients were and the Israel Society for Cancer Research AACR-KCA JOINT CONFERENCE ON underpinnings of each study. Cancer Research UK (CRUK) of Singapore) and the Fourth Conference PRECISION MEDICINE IN SOLID TUMORS also recognized at the AACR Scholar- (ISCR)—AACR CEO Margaret Foti, PhD, JOINT CONFERENCES AND European Academy of Tumor Immunotherapy on New Horizons in Cancer Research in-Training Award Reception by Peter MD (hc) (above center), met with Israeli Seoul, Korea, November 2018 (EATI) WORKSHOPS CSCO 21ST ANNUAL MEETING (Shanghai, China, November 2017), the A. Jones, PhD, DSc, FAACR, chair of the President Reuven Rivlin (above right) European Association for Cancer Research EORTC-NCI-AACR MOLECULAR TARGETS Xiamen, China, September 2018 AACR awarded prizes to the presenters AACR International Affairs Regional and First Lady Nechama Rivlin at their The AACR collaborated with 12 (EACR) AND CANCER THERAPEUTICS SYMPOSIUM The AACR and CSCO offered a symposium of two highly-rated posters from each Advisory Subcommittee on Africa (above, residence. During her remarks, Dr. Foti international cancer research organizations European Cancer Organisation (ECCO) Dublin, Ireland, November 2018 titled “Update and New Paradigm in meeting. The prizes provided travel third from left). highlighted the progress that has been in 2018 to develop the following joint European Medicines Agency (EMA) Cancer Immunology Research.” support to the presenters, enabling them made against cancer and the importance of conferences, educational workshops, INNOVATION AND BIOMARKERS IN European Organisation for Research and • A s part of a new partnership with the Treatment of Cancer (EORTC) to attend the AACR Annual Meeting. international collaborations to advancing and symposia: CANCER DRUG DEVELOPMENT: A JOINT UICC WORLD CANCER CONGRESS AACR to promote international scientific European Society for Medical Oncology MEETING PRESENTED BY EORTC, NCI, EMA, • L aunched in 2016, the AACR African exchange, the Chinese Society for Clinical that progress. The meeting was coordinated AND AACR Kuala Lumpur, Malaysia, October 2018 (ESMO) TWENTIETH ECCO-AACR-EORTC-ESMO Cancer Researcher Travel Awards provided Oncology (CSCO) launched the CSCO by Miri Ziv (above left), Director General Brussels, Belgium, November 2018 The AACR worked with the UICC to Israel Society for Cancer Research (ISCR) METHODS IN CLINICAL CANCER financial assistance to meritorious early- Young Investigator Travel Awards in of the Israel Cancer Association; in her RESEARCH WORKSHOP organize a session on “Breast Cancer Japanese Cancer Association (JCA) career investigators engaged in cancer remarks, Dr. Foti acknowledged Ms. Ziv for Zeist, The Netherlands, June 2018 Genomic Risk Assessment in Global Korean Cancer Association (KCA) 2018. Administered by the AACR, the her contributions to international cancer Health: Implementation in Low-Resource Latin American Cooperative Oncology Group research in Africa, enabling them to program selected 12 AACR members (LACOG) research and advocacy. Settings.” attend and present their research at the who presented meritorious abstracts at Medical Oncology Group of Australia (MOGA)
24 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 25
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 24-25 6/3/19 11:30 AM HONORING SCIENTIFIC ACHIEVEMENT HONORING FELLOWS OF THE AACR ACADEMY: SCIENTIFIC LEADING PROGRESS AGAINST CANCER
ACHIEVEMENT Established in 2013, the AACR ACADEMY PRESIDENT-ELECT (2018-2019) ESTABLISHES GOVERNANCE AACR ACADEMY PRESIDENT (2019-2021) AACR Academy recognizes AND LEADERSHIP BODY and honors distinguished To formalize its advisory and advocacy roles within the organization, the AACR scientists whose major established a governance structure for the scientific contributions AACR Academy in 2018. This leadership body consists of an elected president- have propelled significant elect, who will serve for one year and then transition to a two-year term as Academy JUDY E. GARBER, MD, MPH, FAACR innovation and progress president at the AACR Annual Meeting 2019, and six elected Steering Committee against cancer. Fellows of AACR ACADEMY STEERING COMMITTEE members who will serve three-year terms. the AACR Academy serve as a vital resource to AACR The following AACR Fellows are inaugural members of the AACR Academy leadership, advancing the leadership body: organization’s mission by
providing scientific guidance CARLOS L. JOAN S. BRUGGE, MICHAEL A. ARTEAGA, MD, PHD, FAACR CALIGIURI, MD, and a powerful voice in FAACR FAACR support of sound science policy.
The AACR Academy gathered at the AACR Annual Meeting 2018 to induct a new class of Fellows. RAYMOND N. TYLER JACKS, PHD, KAREN H. DUBOIS, MD, PHD, FAACR VOUSDEN, PHD, FAACR FAACR
26 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 27
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 26-27 6/3/19 11:30 AM HONORING SCIENTIFIC ACHIEVEMENT
CLASS OF 2018 INDUCTION FELLOWS OF THE AACR ACADEMY CLASS OF 2018
ALAN ASHWORTH, PHD, FRS, FAACR MICHAEL A. CALIGIURI, MD, FAACR LAURIE H. GLIMCHER, MD, FAACR ROGER D. KORNBERG, PHD, FAACR UCSF Helen Diller Family Comprehensive Cancer Center City of Hope National Medical Center Dana-Farber Cancer Institute Stanford University School of Medicine University of California, San Francisco Duarte, California Harvard Medical School Stanford, California San Francisco, California Boston, Massachusetts For elucidating the fundamental mechanisms of natural For his pioneering discovery of the structure and For characterizing the significance of cancer killer cell development and immune surveillance, and for For her central discoveries in the fields of transcriptional function of nucleosomes, and for revolutionizing his commitment to advancing cancer health disparities susceptibility genes, notably BRCA2, in the pathogenesis research and promoting the collection and use of clinical regulation, lymphocyte differentiation, inflammation, and the understanding of the molecular machinery and of cancer, and for his contributions to the establishment samples to guide screening, treatment, and surveillance osteobiology, and for her trailblazing efforts to improve orchestrated mechanisms required for eukaryotic gene of PARP inhibitors as effective therapeutic options for protocols. access to care, health policy, and medical education. transcription. the treatment of various cancers.
RENÉ BERNARDS, DPHIL, FAACR CHI VAN DANG, MD, PHD, FAACR ELIZABETH M. JAFFEE, MD, FAACR ARTHUR D. LEVINSON, PHD, FAACR Netherlands Cancer Institute Ludwig Institute for Cancer Research Sidney Kimmel Comprehensive Cancer Center Calico Life Sciences LLC Amsterdam, Netherlands New York, New York The Johns Hopkins University School of Medicine South San Francisco, California The Wistar Institute Baltimore, Maryland For establishing innovative strategies to categorize Philadelphia, Pennsylvania For his visionary leadership and relentless commitment biomarkers of treatment response and effective For her groundbreaking efforts dedicated to the development to the discovery and development of targeted treatment combinations, and for pioneering the use For illuminating mechanistic links between the MYC of cancer vaccines and vaccine combinations that bypass therapeutics for the treatment of various malignancies, of genetic screening tests to identify and stratify oncogene and cellular metabolism, and for defining tumor-associated immunotolerance, and for exploiting including HER2/neu monoclonal antibodies for the individuals at risk of developing breast cancer. how tumor cell utilization of various energy sources genomic and proteomic technologies to define biomarkers treatment of breast cancer. contributes to cancer progression. required for cancer onset, progression, and metastasis.
BRUCE A. BEUTLER, MD, FAACR DWIGHT GARY GILLILAND, MD, PHD, FAACR RICHARD D. KLAUSNER, MD, FAACR NORMAN E. SHARPLESS, MD, FAACR University of Texas Southwestern Medical Center Fred Hutchinson Cancer Research Center Juno Therapeutics National Cancer Institute At a ceremony on the evening before the Annual Meeting in Chicago, Illinois, Dallas, Texas Seattle, Washington Los Altos Hills, California Bethesda, Maryland the 2018 class of Fellows of the AACR Academy was formally inducted. For his discovery of Toll-like receptors and for For identifying genetic drivers of various hematologic For defining molecular mechanisms of intracellular For his seminal contributions to stem cell biology deciphering the biological mechanisms and signaling malignancies including leukemia, myelodysplastic trafficking, translation, and protein assembly, and for and to demonstrating the relationship between tumor events that govern tumor necrosis factor-mediated syndrome, and myeloproliferative disease, and for leading the creation of national and international programs suppressor activation, cell cycle control, cellular inflammation and innate immune system activation. his contributions to the development of monoclonal to support the spectrum of cancer research, resulting in senescence, and molecular aging in tumorigenesis. antibody-based immunotherapeutics. improved cancer diagnosis and treatment strategies.
28 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 29
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 28-29 6/3/19 11:30 AM HONORING SCIENTIFIC ACHIEVEMENT
AACR President (2017-2018) Michael A. Caligiuri, MD, FAACR, hosts the Awards Dinner at the AACR Annual Meeting 2018. SCIENTIFIC ACHIEVEMENT AWARDS
Progress against cancer requires innovative thinking and discovery across the full spectrum of research. AACR Scientific Achievement Awards and Lectureships recognize innovative investigators in all fields of inquiry and provide research funding to support their next breakthroughs.
The ability of the AACR Scientific Achievement Awards program to identify paradigm-shifting excellence in cancer research was confirmed in October 2018 when AACR member and former member of the AACR Board of Directors James P. Allison, PhD, FAACR, was awarded the Nobel Prize in Physiology or Medicine for his shared discovery with colleague Tasuku Honjo, MD, PhD, of cancer therapy by inhibition of negative immune regulation. Before culminating in this recognition by the international scientific community, Dr. Allison’s career was marked by several AACR awards, including:
• The AACR-CRI Lloyd J. Old Award (2013), (2015; above right), for outstanding basic for innovative research that stimulates new research that holds promise for continued directions in cancer immunology; substantive contributions to progress in the field of cancer. • Th e AACR G.H.A. Clowes Memorial Award (2014), for outstanding accomplishments in basic cancer research; By honoring exceptional scientists in all and scientific areas and at all career stages, AACR Scientific Achievement Awards • Th e Pezcoller Foundation-AACR highlight the critical steps along the path of International Award for Cancer Research progress against cancer.
30 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 31
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 30-31 6/3/19 11:30 AM HONORING SCIENTIFIC ACHIEVEMENT
2018 AWARD RECIPIENTS AND LECTURERS
Twelfth Annual AACR Team Science Award GENOMIC APPROACHES TO PREVENTING AND TREATING ASIAN-PREVALENT CANCERS TEAM
Twenty-Seventh AACR-American Cancer Society Award Fifty-Eighth AACR G.H.A. Clowes Memorial Award Second AACR-Waun Ki Hong Award for Outstanding Twenty-First Pezcoller-AACR International Award for Fourteenth AACR-Irving Weinstein Foundation Ninth AACR Distinguished Lectureship on the Science for Research Excellence in Cancer Epidemiology and SCOTT W. LOWE, PHD Achievement in Translational and Clinical Cancer Extraordinary Achievement In Cancer Research Distinguished Lectureship of Cancer Health Disparities, funded by Susan G. Prevention Research Komen Memorial Sloan Kettering Cancer Center TONY HUNTER, PHD, FAACR JENNIFER A. DOUDNA, PHD, FAACR LESLIE BERNSTEIN, PHD New York, New York PASI A. JÄNNE, MD, PHD The Salk Institute University of California Berkeley CHANITA HUGHES-HALBERT, PHD City of Hope Comprehensive Cancer Center Dana-Farber Cancer Institute La Jolla, California Berkeley, California Medical University of South Carolina Duarte, California Harvard Medical School Charleston, South Carolina Boston, Massachusetts
Twenty-Third AACR Joseph H. Burchenal Memorial Sixth AACR-CRI Lloyd J. Old Award in Cancer Fifteenth AACR Award for Lifetime Achievement in Twelfth AACR Princess Takamatsu Memorial Twenty-First AACR-Women in Cancer Research Eleventh AACR Distinguished Lectureship in Breast Award for Outstanding Achievement in Clinical Cancer Immunology Cancer Research Lectureship Charlotte Friend Memorial Lectureship Cancer Research Research ANTONI RIBAS, MD, PHD JOSEPH R. BERTINO, MD, FAACR LISA M. COUSSENS, PHD DAFNA BAR-SAGI, PHD ZENA WERB, PHD JOHANN S. DE BONO, MD, PHD Jonsson Comprehensive Cancer Center Rutgers Cancer Institute of New Jersey Knight Cancer Institute PATRICK TAN, MD, PHD CHIEA CHUEN KHOR, MBBS, PHD New York University Langone Medical Center University of Califonia San Francisco Institute of Cancer Research and Royal Marsden Parker Institute for Cancer Immunotherapy Center at Rutgers Robert Wood Johnson Medical School Portland, Oregon New York, New York San Francisco, California Team Leader Sutton, United Kingdom University of California Los Angeles New Brunswick, New Jersey Agency for Science, Technology and Research Duke-NUS Medical School (A*STAR) Los Angeles, California Cancer Science Institute of Singapore Singapore Singapore TATSUHIRO SHIBATA, MD, PHD BIN TEAN TEH, MD, PHD The University of Tokyo Duke-NUS Medical School National Cancer Center Cancer Science Institute of Singapore Tokyo, Japan Singapore CHAWALIT PAIROJKUL, MD STEVEN ROZEN, PHD Khon Kaen University Duke-NUS Medical School Khon Kaen, Thailand Singapore NARONG KHUNTIKEO, MD Twelfth AACR Award for Outstanding Achievement in Twelfth Margaret Foti Award for Leadership and Thirteenth AACR-Minorities in Cancer Research Jane SOON THYE LIM, MBBS, MRCP (UK), FAMS Khon Kaen University Eleventh AACR Outstanding Investigator Award for Chemistry in Cancer Research Extraordinary Achievements in Cancer Research Cooke Wright Memorial Lectureship National Cancer Centre Singapore Khon Kaen, Thailand Breast Cancer Research, funded by the Breast Cancer JOHN A. KATZENELLENBOGEN, PHD ISAIAH J. FIDLER, DVM, PHD, FAACR JOHN D. CARPTEN, PHD Duke-NUS Medical School Research Foundation Singapore JACOB SEE-TONG PANG, MD, PHD University of Illinois at Urbana-Champaign University of Texas MD Anderson Cancer Center University of Southern California ANN PARTRIDGE, MD, MPH Chang Gung Memorial Hospital Urbana, Illinois Houston, Texas Keck School of Medicine CHOON KIAT ONG, PHD Linkou, Taiwan Dana-Farber Cancer Institute Los Angeles, California National Cancer Centre Singapore Boston, Massachusetts Agency for Science, Technology and Research SEN-YONG HSIEH, MD, PHD (A*STAR) Chang Gung Memorial Hospital Singapore Linkou, Taiwan
32 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 33
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 32-33 6/3/19 11:30 AM SCIENCE AND EDUCATION SCIENCE AND SCIENTIFIC LEADERSHIP: CATALYZING COLLABORATIONS EDUCATION
The AACR identifies the challenges facing cancer AACR PROJECT GENIE: the consortium was accompanied by an POWERING PRECISION expansion of the data set, as releases in scientists and clinicians; assembles leaders in various MEDICINE January and July increased the number of sequenced tumors by more than 50 percent. fields to address those challenges; and works with As the founder of Project GENIE AACR Project GENIE is now one of the (Genomics Evidence Neoplasia Information academic, industry, and government institutions to largest fully public cancer genomic datasets, Exchange), the AACR is working to deliver with more than 48,000 de-identified on the promise of precision medicine. Built implement solutions that drive progress against cancer. genomic records covering more than 80 upon data sharing between the world’s cancer types. leading cancer centers, AACR Project GENIE is an international cancer registry In February 2018—one year after the that aggregates clinical-grade tumor release of the first data set—members of the sequencing data with limited clinical data to consortium published a paper in the journal build virtual cohorts of patients on whom JCO Clinical Cancer Informatics that detailed detailed outcomes data can be retrieved. the genesis of the project and shared the By offering insights into the relationships perspectives of the founding institutions. between genotype and patient outcome, the The paper, which was intended to share project powers translational and clinical best practices and serve as a guide for other research—facilitating the development organizations who wish to develop their of new therapies, informing the design of own genomic data-sharing consortia, was better clinical trials, and improving clinical among the most read articles in the journal decision-making for the benefit of all in July 2018. cancer patients. AACR Project GENIE is also supporting The increasing momentum of AACR the “2020 by 2020” Presidential initiative Project GENIE over the past year was and collaboration. Announced in March reflected in the number of institutions 2018, this initiative from AACR President expressing interest in joining the (2017-2018) Michael A. Caligiuri, MD, The AACR Think Tank on Members from each AACR Project GENIE participating center and strategic Cancer Health Disparities met in partners gathered at the AACR offices in January for their Winter Summit. consortium, which more than doubled FAACR, will perform genomic sequencing Washington, DC, in October. in size in 2018 as 11 new participating of both tumor and normal tissue from organizations joined the eight founding 2,020 consented African-American cancer participants (p. 36). The expansion of patients by the year 2020 and aggregate this
34 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 35
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 34-35 6/3/19 11:30 AM SCIENCE AND EDUCATION
valuable information with clinical data from AACR PATHOLOGY AACR PROJECT GENIE these patients. The genomic data will be TASK FORCE SCIENTIFIC WORKING GROUPS made publicly available through the Project Recognizing the vital role that pathologists FOUNDING CONSORTIUM PARTICIPANTS GENIE registry and the Oncology Research play in delivering timely and accurate Information Exchange Network (ORIEN) to diagnoses to support the most effective Dana-Farber Cancer Institute benefit researchers who are studying cancer Boston, Massachusetts treatment decisions, the AACR convened AACR scientific working groups facilitate progress and cancer outcomes in African-American Gustave Roussy Cancer Campus a Pathology Task Force in December to Paris-Villejuif, France populations with the goal of addressing this against cancer through collaboration. By building identify ways the association can better The Netherlands Cancer Institute, Amsterdam, on behalf of the serious public health challenge. Center for Personalized Cancer Treatment serve the field. Chaired by Massimo F. Loda, communities around areas of scientific interest, the Utrecht, The Netherlands MD, the task force gathered thought leaders Memorial Sloan Kettering Cancer Center AACR aligns the efforts of its members to address New York, New York AACR THINK TANK ON and stakeholders in academia, industry, and Princess Margaret Cancer Centre CANCER HEALTH DISPARITIES government to survey the challenges facing the most challenging questions in cancer research. Toronto, Ontario, Canada the field of cancer pathology and to develop One of the major goals of Dr. Caligiuri’s The University of Texas MD Anderson Cancer Center innovative solutions to those challenges for Houston, Texas presidential year was to confront and the benefit of cancer patients. Vanderbilt-Ingram Cancer Center overcome the challenges of cancer health Nashville, Tennessee disparities. A major step toward reaching PEDIATRIC CANCER WORKING GROUP (PCWG): FACILITATING this ambitious goal was the formation of CANCER PREVENTION INTERNATIONAL COOPERATION AND COORDINATION NEW CONSORTIUM PARTICIPANTS an AACR Think Tank on Cancer Health SUMMIT: WHITE PAPER ON Disparities. Under the leadership of chair THE FUTURE OF CANCER While the AACR’s PCWG works to address the impact of critical research resources, Children’s Hospital of Philadelphia Cancer Center John D. Carpten, PhD, and cochairs Marcia PREVENTION the scientific challenges facing the pediatric it is imperative that the organizations Philadelphia, Pennsylvania R. Cruz-Correa, MD, PhD, Brian M. Rivers, cancer field, the group also addresses the avoid duplication of effort. Leveraging its Cancer Research UK Cambridge Centre, University of Cambridge In February 2016, the AACR convened PhD, MPH, and Sanya A. Springfield, PhD, logistical challenges that hinder progress for international membership and the AACR’s Cambridge, England a three-day Cancer Prevention Summit, the think tank met in Washington, DC, in children with cancer. One such challenge reputation as an honest broker, PCWG Duke University (Duke Cancer Institute) bringing together nearly 70 scientists, Durham, North Carolina October to address three critical elements of was a lack of coordination between began acting as an intermediary between clinicians, patient advocates, and funders Johanna A. Joyce, PhD, delivers her presentation on "Microenvironmental regulation Herbert Irving Comprehensive Cancer Center, Columbia University the cancer disparities problem: 1) increasing of cancer metastasis and therapeutic efficacy" during the Cancer Immunology two of the largest pediatric cancer drug these consortia in 2018, aligning their New York, New York to set a course for future efforts in cancer participation of underrepresented/minority (CIMM)/Tumor Microenvironment (TME) Working Groups Joint Scientific Session, development consortia, the NCI Pediatric efforts to accelerate the pace of progress Swedish Cancer Institute prevention research. In December, under held during the AACR Annual Meeting 2018. Seattle, Washington patients in clinical trials; 2) developing Preclinical Testing Consortium (PPTC) against pediatric cancer. At the AACR the leadership of chairs Ernest T. Hawk, Providence Cancer Institute key resources to accelerate cancer health in the United States and the Innovative Annual Meeting 2018, the PCWG brought MD, MPH, and Scott M. Lippman, MD, Portland, Oregon disparities research; and 3) training the Therapies for Children with Cancer (ITCC) the consortia together for a special session the summit participants published a Wake Forest University Health Sciences cancer health disparities workforce to meet Pediatric Preclinical Proof-of-Concept to discuss the preclinical models they have Winston-Salem, North Carolina white paper in the AACR journal Cancer emerging needs. Participants in the think Program (P4) in Europe. These consortia developed, the therapeutic agents they The University of Chicago Comprehensive Cancer Center Prevention Research titled “Shaping the Chicago, Illinois tank meeting included James W. Lillard, bring together scientists, clinicians, are currently testing, and opportunities Future of Cancer Prevention—A Roadmap University of California-San Francisco PhD, MBA, associate dean for Research regulators, and patients to develop novel to collaborate for the benefit of pediatric Helen Diller Family Comprehensive Cancer Center for Advancing Science and Public Health.” pediatric cancer therapies. To maximize cancer patients worldwide. San Francisco, California at Morehouse School of Medicine and Vall d’Hebron Institute of Oncology principal investigator of the 2020 by 2020 Barcelona, Spain Initiative; and 2018-2019 AACR President Yale Cancer Center Elizabeth M. Jaffee, MD, FAACR. New Haven, Connecticut
36 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 37
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 36-37 6/3/19 11:30 AM SCIENCE AND EDUCATION
Continued progress against cancer requires a robust SCIENCE EDUCATION, workforce consisting of dedicated scientists and CAREER DEVELOPMENT, clinicians at all career levels. Through its science education and professional development programs, the AND CONTINUING AACR inspires and prepares young people to pursue careers in cancer science and supports these emerging MEDICAL EDUCATION investigators at all stages of their career paths.
RADIATION SCIENCE Preventing and curing cancer through Metabolism to Improve Radiotherapy that MOLECULAR EPIDEMIOLOGY AND MEDICINE (RSM): collaboration is one of the pillars of the explored the critical interface between WORKING GROUP (MEG): NEW CHALLENGES, NEW AACR mission, and RSM joined forces with tumor metabolism and radiotherapy ADDRESSING CANCER COLLABORATIONS two other scientific organizations in 2018 to response. Chaired by Julie Schwarz, HEALTH DISPARITIES advance that mission: The mission of the AACR’s Radiation MD, PhD, Douglas Spitz, PhD, and At the AACR Annual Meeting 2018, Science and Medicine Working Group • A major concern among clinicians is the David Gius, MD, PhD, the workshop MEG worked with the AACR Minorities (RSM; above) is to foster the application lack of cancer drugs intended specifically gathered radiobiologists, radiologists, and in Cancer Research (MICR) Council to of radiation science and medicine to for use with radiation therapy. In radiation oncologists to share the program present an inaugural joint symposium on understand and treat cancer malignancies. February, the AACR partnered with the with basic scientists focused on tumor “Aggressive Cancer Phenotypes in Racial/ In June, RSM advanced that mission by Food and Drug Administration (FDA) metabolism. Ethnic Minority Populations: Opportunities hosting a think tank on Illuminating and the American Society for Radiation • The AACR and ASTRO collaborated and Challenges.” Moderated by MICR Technological Advances and Challenges Oncology (ASTRO) to host a regulatory again to host a workshop on Targeting the Council Chair-Elect Laura Fejerman, in Precision Radiotherapies. Supported in science and policy workshop on Clinical Tumor Microenvironment in Radiation PhD, and MEG Steering Committee Chair part by Bayer Pharmaceuticals, the think Development of Drug-Radiotherapy Oncology in July. The meeting—which Melissa L. Bondy, PhD (above), the session tank convened more than 30 experts in Combinations. The workshop brought was chaired by Wendy Woodward, addressed the greater susceptibility of all areas of radiation science—including together regulators with academic and MD, PhD, and Amato Giaccia, PhD— different minority populations to aggressive radiobiology, medical physics, and industry scientists to identify the drug addressed critical topics such as tumor forms of cancer. nuclear medicine—to highlight current development challenges and to develop a stromal effects on radiosensitivity and and emerging radiotherapy technologies, strategy to overcome them. radioresistance, immune response to address the critical needs of the field, and • In March, the AACR worked with the radiotherapy, and the effect of metabolism discuss the most effective approaches to Radiation Research Society (RRS) to on the tumor microenvironment and the AACR CEO Margaret Foti, PhD, MD (hc) congratulates the inaugural recipients of improving patient care. cohost a workshop on Targeting Cancer efficacy of radiotherapy efficacy. the Margaret Foti Foundation Undergraduate Prizes for Cancer Research.
38 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 39
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 38-39 6/3/19 11:31 AM SCIENCE AND EDUCATION
STUDENT MEMBERS: More than 200 undergraduate students SUPPORTING POSTDOCTORAL CONTINUING MEDICAL MYA ROBERSON, MSPH FOSTERING THE NEXT also attended the AACR Annual Meeting FELLOWS EDUCATION AACR ASSOCIATE MEMBER PAST AACR GENERATION OF CANCER to participate in the Thirteenth Annual The National Postdoctoral Association As an ACCME-accredited provider, the UNDERGRADUATE SCIENTISTS Undergraduate Student Caucus and Poster SCHOLAR (NPA) is a nonprofit member organization AACR offered CME credit at 20 different Competition. The poster competition The AACR continued its long-standing that works to enhance the quality of the meetings in 2018, including ten focused featured presentations from more than support of students interested in careers postdoctoral experience in the United special conferences, three joint conferences, 115 students, whose research projects were in science at the Annual Meeting 2018. States. As a sustaining member of the NPA, two educational workshops, two joint evaluated by leading AACR members. At the annual Special Program for High the AACR expresses its appreciation for the providership activities, and the AACR Presenters of the most highly-rated posters School Students, nearly 300 students were vital contributions of postdoctoral scholars Annual Meeting. AACR journals provided were recipients of the inaugural Margaret welcomed to Chicago to participate in to the cancer research enterprise and another educational resource, offering Foti Foundation Undergraduate Prizes for Mya Roberson is an Associate Member of the AACR and a doctoral interactive lectures on cancer development demonstrates its commitment to expanding credit to investigators for reviewing Cancer Research. Funded by AACR Chief candidate in epidemiology at the University of North Carolina Gillings and prevention and to tour the exhibits and the opportunities available to postdocs manuscripts. A total of 3,611 researchers Executive Officer Margaret Foti, PhD, MD School of Global Public Health. She is studying spatial and temporal poster sessions. In addition, 11 high school through education and training. and clinicians claimed CME credit from (hc) (left), the prizes encourage college patterns in racial disparities in cancer outcomes from a health services students presented their own research and the AACR in 2018, taking advantage of students who are interested in science to perspective, and she hopes to eliminate inequities that exist in breast and received feedback on their projects from In September, the AACR participated opportunities to maintain their professional pursue careers in cancer research. gynecologic cancer outcomes between black and white women in North AACR scientist mentors. in National Postdoc Appreciation Week competence and incorporate new Carolina and nationally. activities by hosting two Cancer Careers knowledge into their practices. Clinics at Drexel University and the In September 2017, Mya attended her first conference as a graduate student. University of Pennsylvania. AACR staff She received an AACR Scholar-in-Training Award, which enabled her to provided participants with advice on present her work at the AACR Conference on the Science of Cancer Health navigating the interview and negotiation Disparities in Racial/Ethnic Minorities and the Medically Underserved. processes, managing the transition to a full- She discussed her transformative experience at the conference in an op-ed time position, and submitting successful published in The New York Times. Prior to that, Mya attended the 2015 and publications and grant applications. 2016 AACR Annual Meetings as an AACR Undergraduate Scholar:
“I am thankful for this life-altering organization and for its commitment to fostering the development of very early career scientists, particularly those from demographic backgrounds underrepresented in cancer research. The AACR has changed my life, and now I will go on to change others.”
40 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 41
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 40-41 6/3/19 11:31 AM SCIENCE AND EDUCATION
AACR meetings and While acknowledging the rich history of its ECCO-AACR-EORTC-ESMO WORKSHOP ON special conference series, the AACR also METHODS IN CLINICAL CANCER RESEARCH MEETINGS AND June 16-22; Zeist, The Netherlands educational workshops advanced its meetings program into new Codirectors: Stefan Sleijfer, MD, PhD, Lee bring the latest advances in scientific areas in 2018. One of the scientific NMAZUO W. OZUAH, MD EDUCATIONAL WORKSHOPS priorities identified by the AACR Board of M. Ellis, MD, Corneel Coens, MSc, and AACR/ASCO METHODS Emiliano Calvo, MD, PhD IN CLINICAL CANCER cancer science to researchers Directors in its Vision 2020 Strategic Plan RESEARCH WORKSHOP was an expanded focus on hematological PARTICIPANT around the world. The INTEGRATIVE MOLECULAR EPIDEMIOLOGY malignancies. To realize this critical vision, WORKSHOP: BRIDGING CANCER BIOLOGY AACR collaborated with 16 the AACR partnered with the organizers of AND PRECISION MEDICINE the International Conference on Malignant July 9-13; Boston, Massachusetts scientific organizations to Lymphoma (ICML)—held semiannually in Director: Thomas A. Sellers, PhD, MPH convene 32 meetings in ten Lugano, Switzerland, since 1981—to bring a Codirectors: Peter Kraft, PhD, and Lorelei version of this premier forum for malignant A. Mucci, ScD, MPH Nmazuo W. Ozuah, MD is an Assistant Professor, Department of Pediatrics, countries in 2018, the most in lymphoma research to the United States. Section of Hematology-Oncology, at Baylor College of Medicine and a In June, the inaugural AACR International MOLECULAR BIOLOGY IN CLINICAL member of the Global Pediatric Hematology-Oncology Excellence (HOPE) its history. The organization ONCOLOGY WORKSHOP Meeting on “Advances in Malignant program at Texas Children's Cancer and Hematology Centers. His main July 22-29; Snowmass Village, Colorado Lymphoma” was held in Boston. Under the interest is improving treatment outcomes for children with cancer in resource- also recognized a significant Director: Ross L. Levine, MD leadership of Scientific Committee chair Ari limited settings, in particular Sub-Saharan Africa. Codirectors: Mark W. Geraci, MD, Christine M. milestone in 2018, which M. Melnick, MD, the meeting employed a Lovly, MD, PhD, and Jean Y. Tang, MD, PhD marked the 30th year of its unique, discussion-driven format to discuss In July, Dr. Ozuah participated in the 2018 AACR/ASCO Methods in Clinical Cancer Research Workshop, an intensive one-week program that teaches recent advances and emerging areas of AACR/ASCO METHODS IN CLINICAL special conferences program. lymphoma research and their potential for CANCER RESEARCH WORKSHOP clinical fellows and junior faculty clinical researchers the essentials of effective To celebrate 30 years of transforming patient care. Going forward, July 28-August 3; Vail, Colorado clinical trial designs of therapeutic interventions in the treatment of cancer. the meeting will be held annually and will Codirectors: Patricia M. LoRusso, DO, Jyoti At the end of the workshop, Dr. Ozuah was awarded the Daniel D. Von Hoff scientific excellence, the AACR alternate between the United States and D. Patel, MD, and Meredith M. Regan, ScD Innovator Award. Named for founding Workshop Director and AACR Past Switzerland, ensuring that hematological President Daniel D. Von Hoff, MD, FAACR, the award recognizes the most invited Nobel Laureate Phillip malignancies remain a critical priority for ACORD—AUSTRALIA & ASIA PACIFIC innovative and impactful protocol developed by a workshop participant. Dr. ONCOLOGY RESEARCH DEVELOPMENT Ozuah’s award-winning protocol—addressing the feasibility of dose-intensive A. Sharp, PhD, FAACR—the the cancer research community. WORKSHOP response-based chemotherapy for pediatric Hodgkin's lymphoma in Malawi— September 9-14; Magenta Shores NSW chairperson of the first special has the potential to profoundly impact pediatric care in Africa: 2018 WORKSHOPS Central Coast, Sydney, Australia conference in 1988—to chair Workshop Held outside U.S. Organizing Committee: Zeba Aziz, MBBS, Gary M. Clark, PhD, Reena Nair, MD, “The AACR/ASCO Vail workshop greatly exceeded my expectations. No an anniversary conference ACCELERATING ANTICANCER AGENT Katrin Sjoquist, MBBS, Martin Stockler, training to date has better equipped me for a career in clinical research. The DEVELOPMENT AND VALIDATION MBBS, and Nirav P. Trivedi, MS, MCh career guidance and networking opportunities through the outstanding on “Convergence: Artificial WORKSHOP course faculty continued past the workshop, further demonstrating a strong May 2-4; Bethesda, Maryland Intelligence, Big Data, and TRANSLATIONAL CANCER RESEARCH FOR commitment to the successful careers of budding investigators in oncology Scientific committee chair Ari M. Melnick, MD, addresses attendees of the AACR Executive Committee: H. Kim Lyerly, MD, BASIC SCIENTISTS WORKSHOP research. I feel empowered to translate the lessons learned into clinical International Meeting on Advances in Malignant Lymphoma, held in Boston in June. Prediction in Cancer.” Richard Pazdur, MD, Gregory Reaman, November 4-9; Boston, Massachusetts research protocols that will ultimately improve the prognosis of children with MD, and Mary Scroggins, MA Codirectors: George D. Demetri, MD, Susan cancer in Sub-Saharan Africa. Thank you for the opportunity to be part of Band Horwitz, PhD, FAACR, and Pasi A. this awesome workshop. Jänne, MD, PhD ”
42 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 43
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 42-43 6/3/19 11:31 AM SCIENCE AND EDUCATION
2018 SCIENTIFIC MEETINGS TARGETING DNA METHYLATION AND SIXTH JCA-AACR SPECIAL JOINT SECOND AACR INTERNATIONAL 30TH ANNIVERSARY AACR SPECIAL TUMOR IMMUNOLOGY AND CHROMATIN FOR CANCER THERAPY CONFERENCE ON THE LATEST ADVANCES CONFERENCE: TRANSLATIONAL CANCER CONFERENCE CONVERGENCE: ARTIFICIAL IMMUNOTHERAPY Meeting Held outside U.S. March 1-4; Atlanta, Georgia IN LUNG CANCER RESEARCH: FROM BASIC MEDICINE, CANCER DISCOVERIES FOR INTELLIGENCE, BIG DATA, AND PREDICTION November 27-30; Miami Beach, Florida SCIENCE TO THERAPEUTICS CLINICAL APPLICATION IN CANCER Cochairs: Stephen B. Baylin, MD, FAACR, Cochairs: James P. Allison, PhD, FAACR, FIFTH AACR-IASLC INTERNATIONAL July 10-12; Kyoto, Japan Held in cooperation with the Latin American October 14-17; Newport, Rhode Island JOINT CONFERENCE: LUNG CANCER Margaret A. Goodell, PhD, and Peter A. Lisa M. Coussens, PhD, Ira Mellman, PhD, Organizing Committee (JCA): Hiroyuki Cooperative Oncology Group (LACOG) Cochairs: Phillip A. Sharp, PhD, FAACR, TRANSLATIONAL SCIENCE FROM THE Jones, PhD, DSc, FAACR and Drew M. Pardoll, MD, PhD BENCH TO THE CLINIC Mano, MD, PhD, Seiji Yano, MD, PhD, and September 27-29; São Paulo, Brazil and William C. Hahn, MD, PhD January 8-11; San Diego, California AACR ANNUAL MEETING 2018 Hiroyoshi Nishikawa, MD, PhD Cochairs: Carlos L. Arteaga, MD, FAACR, Program Committee: Judy E. Garber, MD, INNOVATION AND BIOMARKERS IN AACR Annual Meeting 2018; Chicago, Illinois Chairs: Charles M. Rudin, MD, PhD, and April 14-18; Chicago, Illinois Organizing Committee (AACR): Alice T. Carlos Gil Ferreira, MD, PhD, and Gabriel MPH, FAACR, Richard D. Klausner, MD, CANCER DRUG DEVELOPMENT: A JOINT Charles Swanton, PhD Shaw, MD, PhD, Roy S. Herbst, MD, PhD, A. Rabinovich, PhD FAACR, Aviv Regev, PhD, and Charles L. MEETING PRESENTED BY EORTC, NCI, EMA, Program Committee Chair: Elaine R. AND AACR Cochairs: Tony S.K. Mok, MD, Lecia V. Sequist, and Charles M. Rudin, MD, PhD Sawyers, MD, FAACR Mardis, PhD November 29-30; Brussels, Belgium Second AACR MD, MPH, and Monte M. Winslow, PhD METABOLISM AND CANCER Chairs: Denis A. Lacombe, MD, MSc, and International Conference: CANCER DORMANCY AND TWELFTH BIENNIAL OVARIAN CANCER September 28-October 1; New York, 11TH AACR CONFERENCE ON THE SCIENCE Translational Cancer OBESITY AND CANCER: MECHANISMS RESIDUAL DISEASE RESEARCH SYMPOSIUM New York OF CANCER HEALTH DISPARITIES IN Roberto Salgado, MD, PhD Medicine, Cancer UNDERLYING ETIOLOGY AND OUTCOMES Presented by the Rivkin Center for Ovarian RACIAL/ETHNIC MINORITIES AND THE Cochairs: Jonas C. S. Bergh, MD, Michael A. Discoveries for June 19-22; Montreal, Quebec, Canada Cochairs: Ralph J. DeBerardinis, MD, MEDICALLY UNDERSERVED January 27-30; Austin, Texas Cancer and the AACR Caligiuri, MD, FAACR, Lyndsay N. Harris, Clinical Application; Cochairs: Julio A. Aguirre–Ghiso, PhD, PhD, Tak W. Mak, PhD, FAACR, Joshua In association with the AACR Minorities in São Paulo, Brazil Cochairs: Lewis C. Cantley, PhD, FAACR, September 13-15; Seattle, Washington MD, Tracy G. Lively, PhD, Francesco Pignatti, Ann F. Chambers, PhD, Cyrus M. Ghajar, D. Rabinowitz, MD, PhD, and M. Celeste Cancer Research Council Michael N. Pollak, MD, and Elizabeth A. Cochairs: Frances R. Balkwill, PhD, Mary L. MD, and Victor E. Velculescu, MD, PhD PhD, Christoph A. Klein, MD, PhD, and Simon, PhD November 2-5; New Orleans, Louisiana Platz, ScD, MPH (Nora) Disis, MD, Pamela S. Ohashi, PhD, Dorothy A. Sipkins, MD, PhD Cochairs: Ivis Febus-Sampayo, Laura and Elizabeth M. Swisher, MD FOURTH CRI-CIMT-EATI-AACR TARGETING PI3K/MTOR SIGNALING IMMUNOBIOLOGY OF PRIMARY Fejerman, PhD, Scarlett Lin Gomez, MPH, INAUGURAL AACR INTERNATIONAL CANCER November 30-December 3; Boston, AND METASTATIC CNS CANCER: INTERNATIONAL MEETING PANCREATIC CANCER: ADVANCES IN IMMUNOTHERAPY CONFERENCE: PhD, Augusto C. Ochoa, MD, and Brian M. Massachusetts MULTIDISCIPLINARY SCIENCE TO ADVANCE ADVANCES IN MALIGNANT LYMPHOMA: SCIENCE AND CLINICAL CARE TRANSLATING SCIENCE INTO SURVIVAL Rivers, PhD CANCER IMMUNOTHERAPY Cochairs: Lewis C. Cantley, PhD, FAACR, MAXIMIZING THE BASIC-TRANSLATIONAL September 21-24; Boston, Massachusetts September 30-October 3; New York, Presented in association with the AACR INTERFACE FOR CLINICAL APPLICATION David M. Sabatini, MD, PhD, and Jean J. Cochairs: Ronald M. Evans, PhD, FAACR, New York EORTC-NCI-AACR MOLECULAR TARGETS Cancer Immunology Working Group In cooperation with the International AND CANCER THERAPEUTICS SYMPOSIUM Zhao, PhD Manuel Hidalgo, MD, PhD, Steven D. Cochairs: Nina Bhardwaj, MD, PhD, February 12-15; San Diego, California Conference on Malignant Lymphoma (ICML) November 13-16; Dublin, Ireland Leach, MD, Gloria M. Petersen, PhD, and Christoph Huber, MD, Elizabeth M. Jaffee, SAN ANTONIO BREAST CANCER Cochairs: Hideho Okada, MD, PhD, Robyn June 22-26; Boston, Massachusetts Cochairs: Charles Swanton, MD, PhD, Brian M. Wolpin, MD, MPH MD, FAACR, and Guido Kroemer, MD, PhD SYMPOSIUM S. Klein, MD, PhD, Ignacio Melero, MD, Chair: Ari M. Melnick, MD James L. Gulley, MD, PhD, and Antoni December 4-8; San Antonio, Texas AACR-KCA Joint PhD, and Patricia S. Steeg, PhD Cochairs: Francesco Bertoni, MD, Renier J. INTESTINAL STEM CELLS AND COLON EACR-AACR-ISCR CONFERENCE: THE Ribas, MD, PhD Cochairs: Carlos L. Arteaga, MD, FAACR, Conference on Precision Brentjens, MD, PhD, Bertrand Nadel, PhD, CANCER: BIOLOGY TO THERAPY CUTTING EDGE OF CONTEMPORARY Virginia G. Kaklamani, MD, and C. Kent Medicine in Solid Tumors; THIRD AACR-SNMMI JOINT CONFERENCE CANCER RESEARCH AACR-KCA JOINT CONFERENCE ON Lisa G. Roth, MD, Louis M. Staudt, MD, September 27-30; Washington, DC Seoul, Korea ON STATE-OF-THE-ART MOLECULAR October 9-11; Jerusalem, Israel PRECISION MEDICINE IN SOLID TUMORS Osborne, MD PhD, Christian Steidl, MD, Karin Tarte, Cochairs: Anil K. Rustgi, MD, Johanna IMAGING IN CANCER BIOLOGY AND Cochairs: Richard M. Marais, PhD, November 15-17; Seoul, Korea THERAPY PharmD, PhD, Thomas E. Witzig, MD, and C. Bendell, MD, Hans Clevers, MD, PhD, TARGETING RAS-DRIVEN CANCERS Eli Pikarsky, MD, PhD, and Robert A. Cochairs: Tae-You Kim, MD, PhD, and February 14-17; San Diego, California Wei-Li Zhao, MD FAACR, Christina Curtis, PhD, and Owen December 9-12; San Diego, California Weinberg, PhD, FAACR Charles L. Sawyers, MD, FAACR Cochairs: Todd E. Peterson, PhD, and David Sansom, PhD Cochairs: Frank McCormick, PhD, FAACR, R. Piwnica-Worms, MD, PhD Gideon Bollag, PhD, Karen M. Cichowski, PhD, and Shiva Malek, PhD
44 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 45
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 44-45 6/3/19 11:31 AM SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION SCIENTIFIC REVIEW AND INVESTING IN THE FUTURE OF CANCER RESEARCH GRANTS The AACR Grants Program advances the frontiers of cancer ADMINISTRATION science for the benefit of cancer patients by investing in promising basic, translational, and clinical researchers at all career levels. Over the last 20 years, the program has distributed more than $86 million in vital support through the work of the AACR Foundation. New and ongoing partnerships with nonprofit organizations, foundations, and pharmaceutical companies fueled a dramatic expansion of the grants program in 2018, enabling the AACR to foster cancer science and develop the next generation of leaders in the United States and around the world.
46 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 47
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 46-47 6/3/19 11:31 AM SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION
Since the AACR Grants Program launched in 1993, AACR grantees have earned more 59 $3.3 million than $70 million in additional funding. In Scientists from 41 institutions were Amount awarded to postdoctoral and BIRGIT KNOECHEL, addition, they have published more than funded by AACR grants in 2018; these clinical fellows in 2018, providing MD, PHD 700 original research articles on innovative investigators received more than $10 critical resources to spark the career AACR GRANTEE cancer science and technologies, including million in support of research across the development of the next generation the identification of novel cancer targets and spectrum of cancer science. of cancer scientists. The 2018 pathways as well as potential therapeutics. awards included the Debbie’s Dream These articles have been cited more than Foundation-AACR Gastric Cancer 58,000 times, exemplifying the impact that 642 Research Fellowships (right), which AACR grantees have on the field. Applications for AACR grants were provided $50,000 each to support four evaluated in 2018. Birgit Knoechel, MD, PhD, is a pediatric oncologist at Dana-Farber Cancer fellows working on mentored gastric In 2018, the AACR partnered with Institute and an assistant professor of pediatrics at Harvard Medical School cancer research. AstraZeneca and Bayer to offer a unique who focuses on acute lymphoblastic leukemia (ALL), the most commonly funding model designed to foster 276 diagnosed childhood leukemia. In 2016, she was awarded the AACR-Aflac collaboration between academic research Expert scientists served on 17 scientific Inc. Career Development Award for Pediatric Cancer Research to study the centers and the pharmaceutical industry. review committees to select the 2018 mechanisms of enhancer rewiring in drug resistant T-cell ALL (T-ALL), $1.9 million The Stimulating Therapeutic Advancements grant recipients. The AACR is a trusted Amount awarded to eight junior faculty a form of ALL that frequently develops resistance to treatment. The data through Research Training (START) grants administrator of research support, in 2018 to support the launch of their generated through that grant led Dr. Knoechel to new research projects, are among the first of their kind in non- providing scientific oversight and expert independent research careers. one of which resulted in her receiving the inaugural AACR-The Mark profit grantmaking, offering postdoctoral peer review that is fast, flexible, rigorous, Foundation NextGen Grant for Transformative Cancer Research in 2018: and/or clinical research fellows the and transparent. opportunity to spend one year of their $7.5 million “As a first-year clinical fellow, I took care of two teenage boys with [T-ALL], training conducting research onsite at a Amount awarded through partnerships both of whom relapsed very quickly after starting treatment. This experi- pharmaceutical company. with the pharmaceutical industry, ence made me realize the urgent need to identify novel treatment strategies including new partnerships with for these high-risk patients and novel biomarkers that predict who will In addition, through the support of the Johnson & Johnson and Loxo Oncology benefit most from these new therapeutic approaches. Johnson & Johnson Lung Cancer Initiative, and expanded partnerships with AACR offered three new Team Science AstraZeneca and Bayer. I am so grateful for this support [from the AACR], as it has allowed me to grants focused on lung cancer interception ask transformative scientific questions and has been instrumental toward and prevention. The AACR-Johnson & establishing myself as an innovative translational scientist. This [NextGen] Johnson Lung Cancer Innovation Science grant will provide crucial funds toward our study of intratumor epigenetic Grants are expected to drive innovation heterogeneity as the basis for diverse treatment outcomes for difficult to by supporting collaborative team science treat cancers in children.” focused on identifying novel approaches to the prevention, interception, and cure of Learn more about Birgit’s story: AACR.org/Birgit lung cancer.
48 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 49
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 48-49 6/3/19 11:31 AM SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION
THE AACR AND STAND UP TO CANCER: PARTNERS IN PROGRESS
In 2018, Stand Up To Cancer (SU2C) marked its tenth SU2C SUMMITS: REVIEWING • Pancreatic Cancer Mini-Summit. Because of its devastating effects on cancer PROGRESS, CHARTING patients and the limited treatment options available, pancreatic cancer has always year of accelerating the delivery of new therapies FUTURE DIRECTIONS been a major focus of SU2C. At the AACR Annual Meeting in April, SU2C joined with the Lustgarten Foundation to announce the launch of the Pancreatic Cancer Collaboration and accountability are critical to cancer patients by supporting collaboration Collective, a formal strategic partnership to accelerate research to improve outcomes elements of the SU2C funding model. By for pancreatic cancer patients. In August, the AACR organized a summit focused bringing together grantees on a regular and innovation in translational cancer research. exclusively on pancreatic cancer. Supported by the Lustgarten Foundation and basis, SU2C and the AACR monitor the Cancer Research UK, the summit gathered about 100 leaders in the field—including The AACR has proudly served as SU2C’s Scientific progress of funded research projects and 2018-2019 AACR President Elizabeth M. Jaffee, MD, FAACR (above right)—to encourage project leaders to explore new review progress and explore new collaborations. Partner throughout those ten years, providing expert opportunities to work together.
peer review, scientific oversight, policy guidance, • Annual Scientific Summit. In January, NEW SU2C MULTIPLE MYELOMA DREAM TEAM: SCREENING AACR staff worked with the SU2C AND INTERCEPTION OF PRECURSOR MYELOMA communications, and grants administration to ensure Scientific Advisory Committee to host The primary element of the SU2C funding model is the Dream Team, a scientific task the largest Scientific Summit in SU2C’s force focused on a specific cancer problem that incentivizes collaboration among that SU2C’s groundbreaking funding models deliver ten-year history. Dream Team leaders and leading researchers from different institutions. At the AACR Annual Meeting in individual grant recipients reported on the outstanding results. April, SU2C announced the launch of a new $10 million Dream Team to address the status of their research programs. Guest challenge of multiple myeloma. speakers at the summit included Norman E. Sharpless, MD, FAACR, director of the A cancer afflicting the plasma cells of the blood, multiple myeloma is often not National Cancer Institute, and Martha diagnosed until its later stages, and patients do not receive treatment until their Donoghue, MD, clinical lead on the FDA’s disease has progressed and they have overt end-organ damage. Led by Irene Ghobrial, Gastrointestinal Cancers Team. MD, and Ivan M. Borrello, MD, this new Dream Team seeks to change the disease treatment paradigm by characterizing the genomic, epigenomic, microenvironmental, and immune regulators of progression, and developing effective strategies to intercept disease progression.
50 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 51
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 50-51 6/3/19 11:31 AM SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION
PHILLIP A. SHARP INNOVATION IN COLLABORATION AWARDS Through its focus on team science and its emphasis on interaction at annual Scientific Summits, SU2C has fostered a community of leading researchers addressing the most difficult challenges in cancer research. The Phillip A. Sharp Innovation in Collaboration Awards encourage members of that community to identify new research questions and form new teams to answer them. Named for Phillip A. Sharp, PhD, FAACR, chair of the SU2C Scientific Advisory Committee, the awards provide these new teams with support to accelerate progress for the benefit of cancer patients. The 2018 Sharp Awards provided $250,000 grants to each of the following five teams: • Defining Effective T-Cell Response in Viral and Nonviral Gynecologic Cancers Leaders: Claire F. Friedman, MD, and Marta Łuksza, PhD • Cupid-Seq—High Throughput Transcriptomic Spatial Mapping of SIXTH SU2C TELECAST: This great organization brings the scientists together and makes Immune-Tumor Interactions in the RAISING AWARENESS “ Microenvironment AND FUNDS FOR CANCER sure the funding goes to the best research that will save lives Leaders: Raul Rabadan, PhD, and Dan A. RESEARCH now. With dedication and brilliance, the American Association for Landau, MD, PhD • Characterizing Immuno-variability • Studies of Colorectal Cancer Patient- On September 7, with the support of the Cancer Research makes it all work. • Interrogating Impact of Epigenetic in Children following Standard of Derived Organoids to Validate AACR, SU2C produced its sixth biennial ” Modifiers on Durable Reprogramming Care Treatment to Enable Precision Candidate Biomarkers of Resistance to telecast. The broadcast raised more than of Exhausted CD8 T Cells in Patients Assignment to Immunotherapy Trials Natural Killer Cells $123.6 million in pledges collectively in the with NSCLC Treated with PD-1 Leaders: Trevor J. Pugh, PhD, and David Leaders: Michal Sheffer, PhD, and Hugo J. United States and Canada to support SU2C’s Blockade M. Barrett, MD, PhD G. Snippert, PhD innovative collaborative research programs. Leaders: E. John Wherry, PhD, and Support for this award includes $125,000 Funding for this grant was provided by During the broadcast, actor Ken Jeong, MD Matthew D. Hellmann, MD from the Emily Whitehead Foundation. the C4C Fund. (above left), described the role of the AACR:
52 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 53
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 52-53 6/3/19 11:31 AM POLICY AND ADVOCACY POLICY AND SCIENCE POLICY AND GOVERNMENT AFFAIRS ADVOCACY
The AACR Office of Science Policy and Government Affairs is an authoritative source of information for policy makers and regulators about the critical value of cancer research. In 2018, the AACR was a powerful voice for the cancer research community, advocating for investments in cancer research; supporting evidence-based policies that advance cancer research, prevention, and treatment; and providing expert guidance based upon the best available science.
ADVOCATING FOR ROBUST ANNUAL FEDERAL AACR associate members gathered in Washington in February for the third annual FUNDING INCREASES AACR Early-Career Investigator Hill Day. The AACR led efforts to make public health a continued national priority in 2018, working with individuals and organizations in the broader medical research community to advocate for robust, sustained, and predictable annual funding increases for medical research. These efforts resulted in a $2 billion FY2019 budget increase for the National Institutes Participants in the sixth annual Rally for Medical of Health (NIH), $179 million of which is directed to the National Cancer Research Hill Day. The AACR is a founding Institute (NCI). The AACR also successfully advocated for $20 million organizer of the event, which brought advocates for the Food and Drug Administration (FDA) Oncology Center of on behalf 350 partnering organizations to Capitol Hill in September 2018 to call on Congress to make Excellence in the FY19 draft funding bills. biomedical research funding a national priority.
54 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 55
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 54-55 6/3/19 11:31 AM POLICY AND ADVOCACY
• AACR Cancer Progress Report 2018: Harnessing Research Discoveries for EDUCATING, ADVOCATING, AND ADVISING ON Patient Benefit. The keystone of AACR’s advocacy efforts is the AACR Cancer FUNDAMENTAL CANCER HEALTH POLICY ISSUES Progress Report. In September, the AACR presented the eighth annual report As a trusted source of cancer information, the AACR engages lawmakers and to members of Congress and their staffers at a briefing on Capitol Hill. AACR government agencies in discussions of science-based policies that can accelerate President Elizabeth M. Jaffee, MD, FAACR (center right), and Chief Executive progress in the prevention and cure of all cancers. Officer Margaret Foti, PhD, MD (hc) (far right) joined cancer survivors and leading experts to highlight the benefits of federally funded cancer research, • E-Cigarettes: The State of the Science and Reducing Youth Uptake. In from supporting advances like CAR-T immunotherapy to reducing cancer July, the AACR held a congressional briefing about the growing incidence of health disparities. Rep. Ted Poe (R-TX), a leukemia survivor whose story was e-cigarette use among youths (right). Cosponsored by Senator Dick Durbin included in the report, was a featured speaker at the briefing. (D-IL) and Representative Jackie Speier (D-CA), the briefing addressed the • Rally for Medical Research Hill Day. As the founding organizer of the Rally state of the science around e-cigarettes, recent research on the use, sale, and for Medical Research, the AACR worked with 350 partnering organizations marketing of e-cigarettes, and potential policy solutions. Participants discussed to organize the Rally for Medical Research Hill Day, bringing hundreds of options for halting youth vaping, balanced against the need for research advocates from across the country to Capitol Hill in September to advocate to determine the efficacy of e-cigarettes as a smoking cessation aid. [For a for making NIH funding a national priority. The associated Rally for Medical summary and video of the complete briefing, visit the AACR blog, Cancer Research National Day of Action enabled individuals across the country to Research Catalyst, at AACR.org/Ecig.] participate by contacting their legislators directly and posting social media • Advocating for the Elimination of Human Papillomavirus (HPV). In messages in support of sustained increases to the NIH budget. June, the AACR joined five other national cancer organizations and all 70 • 2018 Capitol Hill Days. In addition to the Rally for Medical Research Hill Day, NCI-designated cancer centers in issuing a Consensus Statement urging the AACR provided two other opportunities in 2018 for researchers, physician- increased HPV vaccination rates and screening measures to achieve the goal of scientists, cancer survivors, and advocates to present the case for federal eliminating HPV-related cancers. investment in cancer research. In February, the AACR brought 15 associate • Providing Expert Recommendations to Policy Makers and Regulators. members to Washington for the third annual AACR Early-Career Investigator Throughout 2018, the AACR worked with legislators to provide expert Hill Day. The early-career scientists completed over 30 visits to House and Senate comments on draft legislation and provided guidance to regulators by offices, where they had the opportunity to discuss the importance of federal attending public hearings and submitting public comments. The AACR funding in sustaining and expanding the cancer research workforce. In April, the provided guidance to the FDA on five occasions, informing the discussion of AACR continued its annual partnership with the Association of American Cancer the regulation of e-cigarettes and tobacco products as well as the structure and Institutes (AACI) to bring stakeholders from across the cancer community to function of the FDA Oncology Center of Excellence. Capitol Hill, including directors and representatives from the 70 NCI-designated cancer centers (right). The participants in the 2018 AACR-AACI Hill Day provided insights on the impact of cancer research funding to congressional offices, including those of leading members in the House and Senate.
56 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 57
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 56-57 6/3/19 11:31 AM POLICY AND ADVOCACY
FOSTERING DIALOGUE cancers. However, little progress has • FDA-AACR Nonclinical Models for Safety Assessment of Immuno-oncology Products SURVIVOR AND PATIENT ADVOCACY BETWEEN REGULATORS AND been made toward developing specific Workshop. In September, the AACR joined the NCI and the FDA to host a workshop to THE CANCER RESEARCH drug-radiotherapy combinations. In address the scientific and practical aspects of developing models for the study of immuno- February, the AACR partnered with COMMUNITY oncology products. Participants discussed current challenges and opportunities in the use SCIENTIST↔SURVIVOR presented with the AACR Distinguished the FDA and the American Society The AACR is the authoritative voice of cancer research, of nonclinical models to predict toxicities of immune checkpoint inhibitors and stimulators PROGRAM Award for Exceptional Leadership in Cancer To accelerate progress against cancer, the for Radiation Oncology (ASTRO) to in patients. using meetings, publications, and other programs to Science Policy and Advocacy in recognition AACR promotes engagement between the convene a two-day workshop on the topic, The cornerstone of the AACR’s survivor of her two decades of dedication to patient cancer research community and federal bringing stakeholders together to discuss disseminate breakthrough discoveries made by scientists and patient advocacy efforts is the advocates through this remarkable and regulators. The Regulatory Science and the problem and devise a path forward. Scientist↔Survivor Program (SSP), which and clinicians. Equally important, the AACR’s Survivor impactful program. During the life of this Policy track at the AACR Annual Meeting The outcomes of the workshop were brings patient advocates together with program, more than 500 advocates from 2018—which included 10 sessions on a large summarized in an article published in the and Patient Advocacy programs give a voice to cancer scientists and clinicians to attend sessions all over the world have participated in this range of topics, including pediatric cancer AACR journal Clinical Cancer Research. at AACR scientific meetings. Participants educational experience. drug development, real-world evidence, patients, providing forums that empower patients to tell attend sessions with their AACR scientist • FDA-AACR-SGO Drug Development and CAR-T therapies for solid tumors— mentors, gaining an understanding for Gynecologic Malignancies their stories and share their perspectives with the cancer Nearly 40 patient advocates participated was a major component of this effort. In of the innovative science behind Workshop. The development of new in the SSP in 2018, joining scientist and addition, the AACR partnered with the research community. treatment decisions while providing their treatments for cancers of the uterus, clinician mentors at the AACR Annual FDA to host three workshops on cutting- counterparts with vital patient perspectives. ovaries, cervix, and vulva is vital to reduce Meeting in April and the Science of Cancer edge issues in cancer regulatory science in mortality rates for these diseases. In June, Health Disparities conference in November. 2018. These workshops brought together In 2018, the AACR celebrated the 20th the AACR worked with the FDA and Annual Meeting program participants leading experts from industry and academia anniversary of the SSP—the longest- the Society of Gynecologic Oncology included patient advocates from Trinidad along with regulators from the FDA to running survivor program in the cancer (SGO) to organize this workshop (right), and Tobago, Japan, and Canada. During the discuss challenges and opportunities for research community. This milestone creating a forum for open discussion Annual Meeting, two AACR members were advancement in critical areas: was commemorated during the opening among stakeholders on the way forward named Emeritus Mentors in recognition of ceremony of the AACR Annual Meeting • FDA-AACR-ASTRO Clinical for the diagnosis and treatment of both their long-standing commitment to the SSP. 2018 with a video highlighting the Development of Drug-Radiotherapy common and rare gynecologic cancers. The advocates thanked Peter Kuhn, PhD, history of the program and charting its Combinations Workshop. In the era Presenters at the workshop highlighted and Christopher Kissinger, PhD, for sharing future direction. In addition, Anna D. of precision medicine, the combination the unique molecular characteristics of their time and expertise with program Barker, PhD (left)—who founded the of radiation and targeted therapy holds rare gynecologic cancers that can serve as participants for more than three years. Scientist↔Survivor Program with AACR potential for the treatment of many effective therapeutic targets. CEO Margaret Foti, PhD, MD (hc)—was
58 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 59
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 58-59 6/3/19 11:31 AM POLICY AND ADVOCACY
CANCER TODAY MAGAZINE AACR DISTINGUISHED Under the leadership of editor-in-chief Cancer Today—the AACR’s magazine for cancer patients, William G. Nelson, MD, PhD, Cancer Today survivors, and caregivers—provides vital information pursued two major initiatives in 2018 to LEADERSHIP AWARDS for anyone navigating the challenges of cancer diagnosis, expand its presence among patients and treatment, and survival while also offering a platform their loved ones: for patients to share stories of their journey with cancer. During the opening ceremony of the AACR Annual Meeting Now in its seventh full year of publication, the magazine • In February, the Cancer Today website was continues to tackle important cancer topics in a serious, re-launched with a new format that makes 2018, the AACR honored outstanding men and women comprehensive way. Among the most compelling stories it easier for readers to find late-breaking published in 2018 were the following: news about cancer research, new cancer who have contributed substantially to cancer research with therapies, prevention strategies, and Distinguished Leadership Awards. clinical trials. The new website features • “Searching Blood for Cancer Clues” (Spring 2018). more original stories, and its mobile- Liquid biopsies offer a new way to analyze a tumor’s friendly design enables the editorial staff genetics and to measure treatment response. But to share more content with the magazine’s questions remain about whether these tools will help growing social media following. Traffic oncologists more effectively choose treatments for to Cancer Today online has more than patients. doubled since the launch of the new • “Liver Cancer on the Rise” (Spring 2018). More site, expanding the reach of this vital people are being diagnosed with liver cancer. publication. Contributing editor Sue Rochman examines how AACR Distinguished Award for Extraordinary AACR Distinguished Award for Exceptional Leadership AACR Distinguished Public Service Award for AACR Distinguished Award for Extraordinary Scientific • In March, the Cancer Today staff Scientific Achievement and Leadership in Breast in Cancer Science Policy and Advocacy Exceptional Leadership in Cancer Advocacy Innovation and Exceptional Leadership in Cancer avoiding exposure to risk factors like cigarette established an online book club to offer Cancer Research ANNA D. BARKER, PHD COLONEL JAMES E. WILLIAMS (RETIRED) Research and Biomedical Science smoking, obesity, and hepatitis B and C could cut C. KENT OSBORNE, MD PHILLIP A. SHARP, PHD, FAACR readers an opportunity to engage with the Arizona State University Camp Hill, Pennsylvania liver cancer deaths in half. Baylor College of Medicine Tempe, Arizona Massachusetts Institute of Technology magazine staff and other cancer patients, Houston, Texas A prostate cancer survivor, Colonel Cambridge, Massachusetts • “Pushing the Immune System to Its Limits” caregivers, survivors, and advocates. Led As the chair of the AACR Public Education Williams is an alumnus of the AACR (Summer 2018). Associate editor Kate Yandell writes by senior editor Marci A. Landsmann, Dr. Osborne has not only made A Nobel laureate and Fellow of the AACR Committee from 1992-2001, and later as Scientist↔Survivor Program and has been about how, while immunotherapy drugs have shown each quarter the club featured a book that groundbreaking research contributions, but Academy, Dr. Sharp was the program chair the founding chair of the reconstituted a passionate advocate for funding and remarkable success in some cancer patients, they shared a unique perspective on the cancer he has also provided vision and leadership for the inaugural AACR Special Conference Science Policy and Legislative Affairs research dedicated to men’s health issues— carry an array of side effects that can be challenging experience—whether by illuminating a to the field of breast cancer science and in 1988, and he currently serves as chair Committee from 2001-2002, Dr. Barker in particular, the need for improved care for to monitor and treat. complex scientific topic or describing medicine. Since 1992, he has served as of the Scientific Advisory Committee for has been instrumental in defining and men from racial and ethnic minorities. He a common survivor experience or a codirector of the San Antonio Breast Stand Up To Cancer. He has consistently • “New Tactics for Bladder Cancer” (Fall 2018). After achieving the AACR’s science and public shared his story in the Summer 2016 issue challenge. Online discussion of each book Cancer Symposium (SABCS), which is demonstrated his extraordinary dedication decades of minimal advances in the treatment of policy goals. In addition, her efforts to of Cancer Today, and he serves as a member culminated in a live online conversation considered the world’s largest and most ↔ to the AACR and its mission. bladder cancer, research and new therapies are on launch the AACR Scientist Survivor of the magazine’s Editorial Advisory Board. prestigious conference on breast cancer. the upswing, bringing options and hope to those who with the author on the magazine’s Program—which celebrated its 20th face the disease. Facebook page. anniversary in 2018—established the AACR as a leader in survivor and patient advocacy.
60 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 61
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 60-61 6/3/19 11:31 AM MEMBERSHIP MEMBERSHIP BY THE NUMBERS
The AACR’s ambitious mission to prevent and cure ACTIVE MEMBERS EMERITUS MEMBERS Established laboratory researchers, Active members who have reached the age all cancers is driven by its members. More than physician-scientists, clinicians, and of 70 years 40,000 member scientists, clinicians, and other population scientists AFFILIATE MEMBERS health care professionals in 120 countries around ASSOCIATE MEMBERS Other health care professionals the world advance the frontiers of understanding Young laboratory scientists and (practicing oncologists, nurses, laboratory physicians-in-training (graduate students, technicians, non-scientific corporate in all areas of inquiry, from epidemiology, medical students and residents, and professionals, and patient advocates) clinical and postdoctoral fellows) ished laboratory researchers, physician- prevention, early detection, and interception, to scientists, clinicians, and population basic, translational, and clinical research. AACR STUDENT MEMBERS Undergraduate and high school students programs foster communication and collaboration among these members, aligning their efforts and
catalyzing progress for cancer patients. Note: Totals may not equal 100% due to rounding.
MEMBERS BY CATEGORY
Student Members 7% Emeritus Members 6%
A liate Active Members 6% Members 48%
Associate Members 33%
62 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 63
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 62-63 6/3/19 11:31 AM MEMBERSHIP
4,888 MEMBERS BY LOCATION MEMBERS BY GENDER AACR MEMBERSHIP: New members joined the AACR in 2018. DIVERSIFYING THE CANCER WORKFORCE International Women 30% 63 40% Nobel laureates have been Men The AACR fosters diversity 56% members of the AACR, including United James P. Allison, PhD, FAACR, States in the cancer research who was awarded the Nobel 70% workforce through the Prize in Physiology or Medicine Not Indicated efforts of three vital in October 2018 for his shared 4% discovery of cancer therapy by groups: Minorities in Cancer inhibition of negative immune regulation. Research (MICR), Women in Cancer Research (WICR), 3,416 and the Associate Member Individuals have been AACR MEMBERS BY RACE/ETHNICITY MEMBERS BY WORK SETTING members for more than 25 years. Council (AMC). Through
Foundation/Advocacy Government 4% training and mentorship, Native American Native Alaskan/Native Hawaiian/ Organization 1% 140 0.2% Other Pacific Islander 0.2% Industry/Private these groups empower Individuals have been AACR Sector 15% members for more than 50 years. Hispanic Other/ Not Indicated talented scientists from or Latino 5% 11% Nonprofit Research populations that have been Institute 3% 120 Caucasian African historically underrepresented 47% American/ Academic Countries are represented by Other/Not Black 50% AACR members. 4% Indicated 2% in the scientific community— Cancer Center ensuring that the AACR 277 Asian 34% 14% membership more Patient advocates are members of Hospital/ the AACR. Medical Center/ comprehensively reflects the Early-career scientists participating in a roundtable discussion at the Minorities in Cancer Research Professional Clinic 10% Advancement Session on "Navigating the Road to a Successful Career in Cancer Research," held at the AACR patients that it serves. Annual Meeting 2018.
64 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 65
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 64-65 6/3/19 11:31 AM MEMBERSHIP
The AACR’s commitment to promoting diversity in the cancer research community is exemplified by CEO Margaret Foti, PhD, MD (hc). In October, Dr. Foti was honored with the 2018 European Society for Medical Oncology (ESMO) Women for Oncology Award for her role in supporting the career development of women in oncology. Dr. Foti received the award during the Opening Session of the ESMO 2018 Congress in Munich, Germany (below), during which she presented a lecture titled “The Professional Advancement of Women in Oncology: A Matter of Great Urgency for Patients.”
ASSOCIATE MEMBER COUNCIL The highlight of the year-long celebration MINORITIES IN CANCER Driving Innovative Cancer Research WOMEN IN CANCER • The AACR Annual Meeting 2018 also (AMC; 2018 COUNCIL CHAIR: was the announcement of the elimination RESEARCH (MICR; 2018 to Patient Care and Health Equity.” In RESEARCH (WICR; 2018 presented an opportunity for the WICR ALLISON S. BETOF WARNER, of annual dues for AACR associate COUNCIL CHAIR: BRIAN M. November, at the AACR Conference on COUNCIL CHAIR: LUCILE L. council to provide early-career scientists MD, PHD) members—ensuring that the benefits of RIVERS, PHD, MPH) The Science of Cancer Health Disparities ADAMS-CAMPBELL, PHD) with critical career training through a AACR membership will be available to all in New Orleans, MICR hosted a session Professional Advancement Session. Titled AMC serves as the leadership body for MICR is a membership group within the WICR is a membership group within the early-career scientists. titled “Advances in Cancer Disparities “Challenges and Solutions for Wonder AACR associate members, who consist of AACR committed to preventing and curing AACR committed to recognizing women’s Research: Understanding the Drivers vs. Women in Science,” the session featured graduate students, medical students and • In March, 14 associate members cancer while meeting the professional needs scientific achievements and fostering their Passengers” at the Louisiana State Health Annual Meeting Program Chair and residents, and clinical and postdoctoral visited their senators and congressional and advancing the careers of minority career development and advancement in Sciences Center. AACR President-Elect Elaine R. Mardis, fellows. The council develops programs representatives during the Third Annual scientists. cancer research. PhD, who delivered a keynote address on that address the particular needs of early- Early-Career Investigator Hill Day. • The AACR-MICR Jane Cooke Wright • The AACR-MICR Distinguished Lecture • The AACR-WICR Charlotte Friend “Finding Your Inner Wonder(ful).” career scientists. Organized by the AMC and the AACR Memorial Lectureship highlights an Series brings together leading researchers Memorial Lectureship recognizes an Office of Science Policy and Government outstanding scientist who has made • The AACR first offered the benefits of to present the latest developments in outstanding investigator who has made Affairs, the event gave early-career meritorious contributions to the field of membership to early-career scientists in cancer research to students and faculty meritorious contributions to the field of scientists the opportunity to thank their cancer research and who has, through 1988 with the introduction of associate at Minority-Serving Institutions or cancer research and who has, through representatives for their February vote to leadership or by example, furthered the membership. In 2018, the AACR and other educational institutions that serve leadership or example, furthered the pass the Bipartisan Budget Agreement advancement of minority investigators in the AMC commemorated the thirtieth large minority populations in order to advancement of women in science. The Act of 2018—which facilitated a $2 billion cancer research. The 2018 edition of the anniversary of the Associate Member inspire these students and educators to 2018 edition of the lectureship honored increase to the 2018 NIH budget—and lectureship recognized John D. Carpten, category with a series of events at the Annual pursue careers in cancer research. MICR Dafna Bar-Sagi, PhD (above left), of New to advocate for predictable and sustained PhD (above center), of the Keck School of Meeting and throughout the year (above). organized two lecture sessions in 2018 York University Langone Medical Center. funding increases in the future. Medicine of the University of Southern that addressed the critical topic of cancer Dr. Bar-Sagi delivered her lecture, titled California. Dr. Carpten delivered his health disparities. At the AACR Annual “Unraveling Mechanisms of Oncogenic lecture, titled “Towards Understanding Meeting in Chicago, Robert A. Winn, Ras-mediated Tumorigenesis,” at the the Impact of Diversity in Cancer MD, director of the University of Illinois AACR Annual Meeting 2018. Genome Science,” at the AACR Annual Cancer Center, hosted and chaired a Meeting 2018. session titled “From Bench to Community:
66 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 67
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 66-67 6/3/19 11:31 AM LEADERSHIP
Members of the AACR Board of Directors LEADERSHIP for 2018–2019. AACR OFFICERS AND DIRECTORS
The AACR thanks its officers and members of the board of directors for their vision, their wisdom, and their hard work in support of the AACR’s mission.
2017-2018 AACR President Michael A. Caligiuri, MD, FAACR, hands the gavel to incoming (2018-2019) President Elizabeth M. Jaffee, MD, FAACR, during the presidential transfer of power ceremony, which took place during the Annual Business Meeting of Members at the AACR Annual Meeting 2018.
68 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 69
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 68-69 6/3/19 11:31 AM LEADERSHIP
OFFICERS BOARD OF DIRECTORS
President Past President CORY ABATE-SHEN, PHD DAFNA BAR-SAGI, PHD LEVI A. GARRAWAY, MD, PHD EDISON T. LIU, MD ANTONI RIBAS, MD, PHD ELIZABETH M. JAFFEE, MD, FAACR MICHAEL A. CALIGIURI, MD, FAACR Columbia University Irving Comprehensive Cancer Center New York University Langone Medical Center Eli Lilly and Company The Jackson Laboratory University of California, Los Angeles New York, New York Los Angeles, California The Sidney Kimmel Comprehensive Cancer Center at City of Hope National Medical Center New York, New York Indianapolis, Indiana Bar Harbor, Maine Johns Hopkins Duarte, California Baltimore, Maryland
President-Elect Chief Executive Officer ADRIANA ALBINI, PHD RENÉ BERNARDS, PHD, FAACR PHILIP D. GREENBERG, MD GORDON B. MILLS, MD, PHD LILLIAN L. SIU, MD ELAINE R. MARDIS, PHD MARGARET FOTI, PHD, MD (HC) Fondazione Multi Medica Onlus Netherlands Cancer Institute and Utrecht University Fred Hutchinson Cancer Research Center University of Texas MD Anderson Cancer Center Princess Margaret Cancer Centre Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Amsterdam, The Netherlands University of Washington Houston, Texas Toronto, Ontario, Canada The Institute for Genomic Medicine at Nationwide American Association for Cancer Research Milano, Italy Seattle, Washington Children’s Hospital Philadelphia, Pennsylvania Columbus, Ohio
Treasurer ALAN ASHWORTH, PHD, FRS KAREN CICHOWSKI, PHD CARL H. JUNE, MD, FAACR MARTINE J. PICCART, MD, PHD, FAACR DAVID A. TUVESON, MD, PHD Harvard Medical School Jules Bordet Institute WILLIAM N. HAIT, MD, PHD, FAACR Helen Diller Family Comprehensive Cancer Center University of Pennsylvania Perelman School of Medicine Cold Spring Harbor Laboratory (CSHL) Cancer Center University of California Brigham and Women’s Hospital Philadelphia, Pennsylvania Brussels, Belgium Cold Spring Harbor, New York Janssen Research & Development, LLC San Francisco, California Boston, Massachusetts Raritan, New Jersey
70 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 71
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 70-71 6/3/19 11:31 AM LEADERSHIP
AACR FOUNDATION OFFICERS AND OFFICERS TRUSTEES TRUSTEES Eighty-eight cents of every dollar raised by the AACR
Foundation goes to support lifesaving cancer science. Chairman and President Founding Chairman of the Board and President BEVERLY W. AISENBREY MICHAEL A. CALIGIURI, MD, FAACR CATHY FRASER WILLIAM N. HAIT, MD, PHD, FAACR Emeritus RAYMOND N. DUBOIS, MD, PHD, FAACR Retired, Frederic W. Cook & Co. City of Hope National Medical Center Mayo Clinic Janssen Research & Development, LLC The AACR thanks the officers and trustees of the Cortlandt Manor, New York Duarte, California Rochester, Minnesota Raritan, New Jersey Medical University of South Carolina BAYARD D. CLARKSON, MD, FAACR Charleston, South Carolina Memorial Sloan Kettering Cancer Center Foundation for their efforts to maximize the impact of New York, New York donations on the lives of cancer patients.
Vice Chairman Executive Director of the AACR Foundation CARLOS L. ARTEAGA, MD, FAACR NANCY E. DAVIDSON, MD, FAACR JUDY E. GARBER, MD, MPH, FAACR RICHARD A. HEYMAN, PHD WILLIAM H. MEARS JR., JD, CPA MITCHELL R. STOLLER UT Southwestern Medical Center Fred Hutch/University of Washington Cancer Consortium Dana-Farber Cancer Institute Metacrine, Inc.; ORIC Pharmaceuticals Dallas, Texas Seattle, Washington Del Mar, California Brown Brothers Harriman Trust Co. LLC American Association for Cancer Research Boston, Massachusetts Richmond, Virginia Philadelphia, Pennsylvania
Secretary-Treasurer and CEO JAMES V. BUZZITTA, MD FAYE FLORENCE, ESQ. NANCE GUILMARTIN WEN-JEN HWU, MD, PHD Mitchell R. Stoller, Executive Director of the AACR Foundation, thanks MARGARET FOTI, PHD, MD (HC) Hughes Ventures, LLC & Hughes Management, LC Attorney, Non-Profit Board Member Author, Consultant University of Texas MD Anderson Cancer Center Grand Rapids, Michigan Chestnut Hill, Massachusetts Ipswich, Massachusetts Houston, Texas supporters of the AACR at the Partners in Progress Reception during the American Association for Cancer Research AACR Annual Meeting 2018. Philadelphia, Pennsylvania
72 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 73
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 72-73 6/3/19 11:31 AM LEADERSHIP
TRUSTEES (continued) TRUSTEES EMERITI
ELIZABETH M. JAFFEE, MD, FAACR SHERRY LANSING LAURENCE J. MARTON, MD ANIL K. RUSTGI, MD ELLEN V. SIGAL, PHD JOSÉ BASELGA, MD, PHD, FAACR FRANK MCCORMICK, PHD, FAACR The Sidney Kimmel Comprehensive Cancer Center at The Sherry Lansing Foundation Consultant, Board Member, Advisor University of Pennsylvania Friends of Cancer Research Memorial Sloan Kettering Cancer Center University of California, San Francisco Johns Hopkins Los Angeles, California Palo Alto, CA Philadelphia, Pennsylvania Washington, D.C. New York, New York San Francisco, California Baltimore, Maryland
V. CRAIG JORDAN, OBE, PHD, DSC, FAACR JOHN E. LEONARD, PHD GLADYS MONROY, PHD, JD STEPHEN D. RYAN GEOFFREY M. WAHL, PHD, FAACR ELIZABETH H. BLACKBURN, PHD, FAACR CHARLES L. SAWYERS, MD, FAACR University of Texas MD Anderson Cancer Center Vaccinex Inc. Intellectual Property Consultant Merrill Lynch Private Banking and Investment Group The Salk Institute for Biological Studies The Salk Institute Memorial Sloan Kettering Cancer Center Houston, Texas Carlsbad, California Atherton, CA Pittsford, New York La Jolla, California La Jolla, California New York, New York
ELEANOR D. KRESS LINDY LI JOHN E. OXENDINE ANIL SETHI TYLER JACKS, PHD, FAACR Wilmington Trust Retirement and Institutional Community Activist and Entrepreneur Blackstar Management Ciitizen Massachusetts Institute of Technology Services Co. Philadelphia, Pennsylvania Boca Raton, Florida Palo Alto, California Cambridge, Massachusetts New York, New York
74 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 75
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 74-75 6/3/19 11:31 AM LEADERSHIP
International Affairs Committee Annual Meeting Clinical Trials AACR Clinical Cancer Research Awards AACR Team Science Award Committee COMMITTEE FRANK MCCORMICK, PHD, FAACR Committee Committee LUIS A. DIAZ, MD TASK FORCE SCIENTIFIC WORKING NILOFER S. AZAD, MD MICHAEL A. CARDUCCI, MD CHAIRS Nominating Committee LOUIS M. WEINER, MD AACR-Waun Ki Hong Award for CHAIRS GROUP CHAIRS JOSÉ BASELGA, MD, PHD, FAACR AACR Distinguished Lectureship in Outstanding Achievement in Cancer Annual Meeting Education Committee Breast Cancer Research Committee Research Committee LISA M. COUSSENS, PHD, CHAIR Cancer Immunology Working Group VERED STEARNS, MD KORNELIA POLYAK, MD, PHD Publications Committee CHRISTINA CURTIS, PHD, COCHAIR DMITRY I. GABRILOVICH, MD, PHD VICTOR E. VELCULESCU, MD, PHD RICCARDO DALLA-FAVERA, MD, FAACR, COCHAIR AACR-WICR Charlotte Friend Memorial AACR Distinguished Lecture on the Chemistry in Cancer Research LISA A. NEWMAN, MD, COCHAIR Lectureship Committee Science Education and Career DAVID A. TUVESON, MD, PHD, COCHAIR Science of Cancer Health Disparities Working Group CAROLINE DIVE, PHD Advancement Committee Committee JULIAN BLAGG, DPHIL KATHLEEN W. SCOTTO, PHD Satellite Educational Symposia SMITA BHATIA, MD, MPH Pezcoller Foundation-AACR International Committee Award for Cancer Research Committee Molecular Epidemiology Working Group Science Policy and Government Affairs GEORGE D. DEMETRI, MD ELLEN L. GOODE, PHD, MPH AACR Laboratory Research Award MICHAEL B. KASTAN, MD, PHD, FAACR Committee Committee GEORGE D. DEMETRI, MD Pediatric Cancer Working Group SCIENTIFIC ACHIEVEMENT ANNA M. WU, PHD SPECIALTY COMMITTEE CRYSTAL MACKALL, MD AWARD COMMITTEE CHAIRS AACR Science Education and Career Special Conferences Committee CHAIRS Massimo Loda, MD, chair of the AACR Julian Blagg, DPhil, chair of the Advancement Committee Chair AACR Margaret Foti Award for Pathology Task Force. Chemistry in Cancer Research Working CORY ABATE-SHEN, PHD AACR Award for Lifetime Achievement Radiation Science and Medicine Kathleen W. Scotto, PhD (left), Leadership and Extraordinary AACR Cancer Progress Report Steering Group Steering Committee. Working Group presents an AACR-Thomas J. Bardos in Cancer Research Committee Achievements in Cancer Research Tellers Committee Committee Science Education Scholar Award to BENJAMIN G. NEEL, MD, PHD DAVID R. GIUS, MD, PHD Committee ELIZABETH M. JAFFEE, MD, FAACR AACR Pathology Task Force undergraduate student Leah V. Dodds APPOINTMENT PENDING MICHAEL A. CALIGIURI, MD, FAACR MASSIMO LODA, MD during the AACR Annual Meeting 2018. AACR Award for Outstanding Tumor Microenvironment Working Group AACR June L. Biedler Prize for Cancer Achievement in Chemistry in Cancer YIBIN KANG, PHD ANNUAL MEETING AACR-Minorities in Cancer Research Journalism Judging Panel AACR Hematologic Malignancies Research Committee STANDING COMMITTEE CHAIRS COMMITTEE CHAIRS Jane Cooke Wright Memorial Lectureship CLIFTON LEAF, MS Task Force RUTH NUSSINOV, PHD Committee JONATHAN LICHT, MD Continuing Medical Education Annual Meeting Program Committee BRIAN M. RIVERS, PHD AACR Project Genomics Evidence JOHN D. CARPTEN, PHD, CHAIR AACR Cancer Epidemiology and Committee Neoplasia Information Exchange (GENIE) KENNETH C. ANDERSON, MD, FAACR, Prevention Award Committee A. WILLIAM BLACKSTOCK, JR., MD VICE CHAIR AACR Outstanding Investigator Award Steering Committee MARCIA R. CRUZ-CORREA, MD, PHD, ADRIANA ALBINI, PHD for Breast Cancer Research Committee CHARLES L. SAWYERS, MD, FAACR Education and Training Committee VICE CHAIR LAJOS PUSZTAI, MD, DPHIL TODD R. GOLUB, MD, VICE CHAIR ELAINE R. MARDIS, PHD AACR-Cancer Research Institute Lloyd STEPHEN D. HURSTING, PHD, VICE CHAIR J. Old Award in Cancer Immunology PATRICIA M. LORUSSO, DO, VICE CHAIR AACR Princess Takamatsu Memorial Exhibits Committee RICHARD M. MARAIS, PHD, VICE CHAIR Committee Lectureship Committee EDWARD CHU, MD AVIV REGEV, PHD, VICE CHAIR ELLEN PURÉ, PHD ANTONI RIBAS, MD, PHD, VICE CHAIR LEWIS C. CANTLEY, PHD, FAACR BRIAN M. RIVERS, PHD, VICE CHAIR Finance and Audit Committee DAVID A. TUVESON, MD, PHD, VICE CHAIR THOMAS J. LYNCH, JR., MD
76 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 77
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 76-77 6/3/19 11:31 AM AACR FOUNDATION AACR SUPPORTING FOUNDATION PROGRESS MARK SCHONEVELD CANCER SURVIVOR, AGAINST CANCER AACR AMBASSADOR
The mission of the AACR—to prevent and cure all cancers through research, education, communication, collaboration, policy and Mark Schoneveld was diagnosed with grade III anaplastic astrocytoma in 2013. After two brain surgeries, proton therapy, and a course of advocacy, and funding—is an ambitious one. chemotherapy, he has been cancer free for nearly four years. A stay-at-home dad to son Soren and twins Mira and River, Mark focuses on each day, The goal of the AACR Foundation—to provide running to stay healthy in the face of a disease that may return some day.
the full range of resources needed to support Mark began working with the AACR as an Ambassador in 2018, and he ran the AACR's mission—is equally ambitious. in the 2018 AACR Philadelphia Marathon as part of the AACR Runners for Research team to raise money to support lifesaving cancer science: By creating a community of supporters from all sectors of the field—including nonprofit “The piece of the disease that hits me every day is that this day matters, because I’m alive and I can talk and I can walk and I can run. organizations; foundations; industry partners; and I know the promise of research and how it benefits cancer patients today cancer survivors, family, and friends—the AACR like me. And I want to support cancer researchers in any way I can.” Foundation accelerates progress against cancer. Learn more about Mark's story: AACR.org/Mark
AACR Runners for Research team member Mamadou Ba sprints out to the lead in his starting group during the 2018 AACR Philadelphia Marathon. The Runners for Research team helped raise $400,000 to support lifesaving cancer research.
78 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 79
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 78-79 6/3/19 11:31 AM AACR FOUNDATION
EXPANDING INDUSTRY AN EXCITING NEW FUNDING PARTNERSHIPS MODEL TO SUPPORT INNOVATIVE CANCER Industry plays a vital role in the cancer RESEARCH research enterprise, and the AACR’s industry partners increased their critical support of its Since 2016, MPM Capital has managed the programs and initiatives in 2018. The AACR’s UBS Oncology Impact Fund (OIF). The Sustaining Member program expanded to fund, which invests across a spectrum of a total of 26 corporate partners, and two companies that develop transformative cancer longtime AACR supporters made substantial therapeutics, is the first social impact fund financial commitments to advance the to dedicate a portion of its profits specifically AACR’s mission: to cancer research. At the AACR Annual • In February, Johnson & Johnson announced Meeting in April (right), MPM announced a $4.86 million contribution to the AACR, that it had selected the AACR as a beneficiary SECURING THE FUTURE OF the largest single gift ever received from of the OIF, beginning with a $1.2 million gift THE AACR MISSION: a pharmaceutical partner. Supported by to establish the AACR-MPM Transformative DR. BAYARD D. CLARKSON the Johnson & Johnson Lung Cancer Research Grants Program. The grants, which LEGACY SOCIETY Initiative, the gift was used to fund three will be awarded by a Scientific Advisory AACR-Johnson & Johnson Lung Cancer Board established by the AACR, will In 2017, the AACR legacy giving society Innovation Science Grants that support support innovative research that accelerates was renamed in honor of Bayard D. multi-institutional research teams seeking breakthroughs against cancer. Clarkson, MD, FAACR—past president, • Party With a Purpose. Since 2016, the 98, for leading the union’s charitable • AACR Philadelphia Marathon. In novel approaches to the prevention, fifty-year AACR member, Fellow of the LOCAL OUTREACH, AACR has been the exclusive beneficiary efforts over the past 25 years. The Party its second year as the Title Partner of interception, and cure of lung cancer. AACR Academy, and founding chair of GLOBAL IMPACT of this elite fundraising gala. The 2018 With a Purpose Scientific Achievement the AACR Philadelphia Marathon, the the AACR Foundation. Inspired by Dr. • In March, AstraZeneca and its global Party with a Purpose—which was Award was presented to Karen Knudsen, AACR joined the City of Philadelphia in While its industry partnerships continue to Clarkson’s lifetime of service to the AACR’s biologics research and development arm, organized by committee president Beverly PhD, a prostate cancer researcher and the welcoming more than 30,000 participants raise the AACR’s national and international mission, a record number of AACR MedImmune, announced a contribution Goldberg and committee chairs Julia Enterprise Director of the Sidney Kimmel for race weekend, November 17-18. profile, the AACR Foundation maintains members made an endowed, estate, or of $2.9 million to the AACR to support Somers-Morley, John Kroll, John J. Parker, Cancer Center (SKCC) at Jefferson. As The participants included more than a strong presence in its home city of other planned gift to benefit the AACR in 12 fellowships that will stimulate Sr., and Arlene Cohen in partnership with part of her award, Dr. Knudsen selected 300 members of the AACR Runners for Philadelphia—raising funds locally to support 2018. Their generous support will sustain innovative research in the fields of DNA the AACR—focused on prostate cancer Veronica Rodriguez-Bravo, PhD, Assistant Research team, who made their miles the AACR’s mission. the AACR’s ongoing pursuit of its mission damage response and immuno-oncology. research and raised over $500,000 to Professor, Sidney Kimmel Cancer Center matter by raising $400,000 to support to prevent and cure all cancers. Postdoctoral and clinical fellowship • AACR Revolutions for Research. The third support groundbreaking science. at Jefferson, to receive the Friends of lifesaving cancer research. recipients will conduct groundbreaking edition of this annual indoor cycling event the AACR Foundation Early Career research both in an academic was held in October at The Fillmore, a new During the October gala, the Party With Investigator Award. The Early Career environment and at AstraZeneca and Philadelphia music venue (right). Teams a Purpose Distinguished Service Award Investigator Award provides a grant to MedImmune under the guidance of a of cyclists gathered to ride for 90-minute was presented to John J. Dougherty, support Dr. Rodriguez-Bravo’s research dedicated industry mentor. and 180-minute sessions to raise funds to Business Manager of the International on the responsiveness and vulnerability of support the AACR’s mission. Brotherhood of Electrical Workers Local cancer cells.
80 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 81
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 80-81 6/3/19 11:31 AM AACR FOUNDATION
RESEARCH GRANT ACKNOWLEDGMENT FUNDERS OF SUPPORTERS
AACR John and Elizabeth Leonard Family PARTNERS IN PROGRESS PILLARS OF SCIENCE Foundation Aflac, Inc. ANNUAL GIVING SOCIETY VISIONARIES ($1,000,000 OR MORE) 7, 11 Kure It Cancer Research Annual giving offers all donors an Amgen, Inc. Amgen, Inc. 7, 11 opportunity to support lifesaving cancer AstraZeneca Loxo Oncology 7, 11 AstraZeneca research and sustain the mission of the Bristol-Myers Squibb Neuroendocrine Tumor Research 11 Bayer HealthCare, LLC AACR. We gratefully acknowledge those Genentech, a member of The Roche Group 11 Foundation individuals and family foundations who Pancreatic Cancer Action Network Breast Cancer Research Foundation Ocular Melanoma Foundation gave $500 or more, and those special events, Stand Up To Cancer, a program of the 7, 11 Bristol-Myers Squibb Oncology associations, corporations, and foundations Entertainment Industry Foundation Pharmacyclics, LLC that contributed $5,000 or more during the Conquer Cancer Foundation INNOVATORS ($500,000 TO $999,999) Takeda Oncology, Inc. calendar year. Debbie’s Dream Foundation Bayer7, 11 The Mark Foundation for Cancer Research Incyte Corporation7, 11 Genentech BioOncology 1 - AACR Member Triple Negative Breast Cancer Foundation Merck & Co., Inc.7 2 - AACR Board of Directors GlaxoSmithKline Pfizer Oncology7, 11 The QuadW Foundation and the QuadW Effie Tzameli, PhD, (right) Director of Research at the Neuroendocrine Tumor 3 - AACR Foundation Trustee Michele Cleary, PhD (left), Chief Executive Officer at The Mark Foundation, and Janssen Research & Development, LLC Fund of Communities Foundation of Texas Research Foundation, presents the Neuroendocrine Tumor Research Foundation- Michael A. Caligiuri, MD, FAACR (right), AACR President (2017-2018), present the AACR Grant to Pawel Mazur, PhD, (left) at the AACR Annual Meeting 2018. Since 4 - AACR Fellow LAUREATES ($250,000 TO $499,999) inaugural AACR-The Mark Foundation NextGen Grant for Transformative Cancer 2011, the Neuroendocrine Tumor Research Foundation has provided $2,750,000 in 5 - 50 year-plus AACR Member Aflac11 Research to Birgit Knoechel, MD, PhD (center). funding to the AACR to support neuroendocrine cancer research. 6 - AACR Staff Member Debbie’s Dream Foundation 7 - AACR Sustaining Member Estate of Gerda Sitko9, 12 8 - 25-49 year AACR Member Lilly Oncology7, 11 PRESIDENT’S CIRCLE 9 - Dr. Bayard D. Clarkson Legacy Society Neuroendocrine Tumor Research STEWARDS ($100,000 TO $249,999) 10 - AA CR Monthly Giving/ 11 Foundation AbbVie, Inc.11 Loxo Oncology12 Sustaining Hope Club 12 Puma Biotechnology, Inc. Boehringer Ingelheim7, 11 Novartis7, 11 11 - The 1907 AACR Founders Society 7 Takeda Oncology Celgene Corporation7, 11 Novocure12 12 - The Medaled Society Virginia and Bayard D. Clarkson, MD, Ocular Melanoma Foundation12 13 - 15-24 year AACR Member FAACR1, 3, 4, 5, 12 Pharmacyclics, LLC7, 12 14 - Trustee Emeritus Gilead Sciences, Inc.7 Sidney Kimmel Cancer Center at Jefferson12 * - Deceased GlaxoSmithKline7, 11 Susan G. Komen IBEW Local Union 98 The Mark Foundation for Cancer Research12 Kure It Cancer Research11 Triple Negative Breast Cancer Foundation
82 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 83
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 82-83 6/3/19 11:31 AM AACR FOUNDATION
CATALYSTS ($50,000 TO $99,999) Alzheimer’s Association American Heart Association United Way of Greater Philadelphia & Scrub Daddy, Inc. Pamela Bailis Carr & Duff Inc. Tom and Deb Dolan Astellas Pharma US, Inc.11 American Brain Tumor Association American Society of Clinical Oncology Southern New Jersey Geoff Secora and Eun Song Christine Baker Christopher Castello John Dougherty Jean M. Gudas*1, 8, 9 American Cancer Society12 Asian Fund for Cancer Research Cyndi and John A. Secrist, III1, 8 Hamid Band, PhD, MD1 Jill and Webster Cavenee, PhD, FAACR1, 4, 8 Shannon Drew Illumina, Inc.12 Anonymous BD Co. COLLABORATORS ($2,500 TO $4,999) Michael Sitzer Julia Barbour Cement Mason and Plasters Local 592 Paul Driscoll6, 10 1, 2, 4 Sarah and Daniel J. Keating III12 Association of American Medical Colleges Candy and Gil Beyda Alan Ashworth, PhD, FAACR Society for Neuroscience Denise Barlow1 Emily Chen DS Pool Service, Inc. 1, 4, 14 John and Elizabeth Leonard Family Sally J. Bellet, Esq. William J. Blot, PhD1, 8 Elizabeth H. Blackburn, PhD, FAACR SugarHouse Casino Peter Bastian Lo-Nien Chi Andre Duffie Foundation12 Bonnie and Thomas H. Bown II Michael A. Caligiuri, MD, FAACR1, 2, 3, 4, 8 Burberry Americas John Suggs Doreine Carson Beck and Brian Christopher Marilyn Duvall 1 Estate of Daisy Lundsten9 Dr. James S.C. Chao John S. Cargile, MD Charles E. Chalfant, PhD The Wawa Foundation William T. Beck, PhD1, 8 Brian L. Clark Todd Ehrlich Lustgarten Foundation Clayman Family Foundation Nate, Jake, and Lulu Cohen Classic Cake Laura Tyson, PhD Mary Beckerle, PhD1 Cassra Clark Peter D. Emanuel, MD1, 13 Pezcoller Foundation7 Margaret Foti, PhD, MD (hc)1, 3, 8, 12 Conner Strong & Buckelew Companies Coalition for the Life Sciences United Way of Allegheny County Joseph R. Bertino, MD, FAACR1, 4, 5 Cleary, Josen & Trigiani LLP Sean Enderlein SANOFI GENZYME7, 11 Frank M. Vaccaro and Associates, Inc./ Danbro, LP Columbia University Medical Center United Way of Central Maryland Kathleen and Michael Beveridge6 Club R-K Endocrine Society The QuadW Foundation and the QuadW Fund Tri-State Administrators, Inc. Dietz & Watson, Inc. Dana-Farber Cancer Institute Weill Cornell Medical College of Biophysical Society Arlene and Stephen Cohen Ropizah Ervin of Communities Foundation of Texas12 Friends of Cancer Research Kathy and Jack Donnelly Angel and Jerome DiPentino Cornell University Kaisha Blackstone Colaluca Family Charity Fund Anne Estey 3 Wayne Griswold Lisa and Raymond N. DuBois, Faye Florence Bladder Cancer Advocacy Network Cold Spring Harbor Laboratory Cancer Ctr. EveryLife Foundation for Rare Diseases COMMUNICATORS ($25,000 TO $49,999) Hatzel & Buehler, Inc. and Bluestone MD, PhD, FAACR1, 3, 4, 13 Flyers Charities HONOR ROLL ($500 TO $2,499) Clara D. Bloomfield, MD, FAACR1, 4, 8 Trent Collings Eye Designs, LLC 1, 13 American Society for Radiation Oncology Communications, Inc. Cathy Fraser3 Friends of the AACR Foundation Lucile L. Adams-Campbell, PhD Beth Blum Daniel Comer Meredith Fay 7, 12 Astex Pharmaceuticals, Inc. Burton Hong and Audrey Cheng9 Dr. Daniel and Beverly Goldberg Eitan and Mali Gertel Aryana Alborzi Arlene Bobb Stacey Cooper Joni Fearheiley 12 Conquer Cancer Foundation iHeartMedia Richard A. Heyman, PhD1, 3 Haveron Total Health, P.A. Gracita Alfeche Sandra and Paul Bomze Alliyah Corley Cheryl S. Fejes 12 1, 4, 8 Daiichi Sankyo, Inc. Irving Weinstein Foundation12 Hilton Philadelphia/Penn’s Landing Susan Band Horwitz, PhD, FAACR Alliance for Aging Research Lauren Boothe Alyssa Costas Mark and Nancy Feldscher 9 1, 4 Gloria W. Heath* V. Craig Jordan, OBE, PhD, FAACR1, 3, 4, 8, 12 Independence Blue Cross Jenny Price and Tony Hunter, PhD, FAACR AmazonSmile Foundation Kelly Borges Joseph E. Cuffari Jack Ferguson Ipsen Biopharmaceuticals, Inc. The Linus Group Laborers District Council of Philadelphia & International Brotherhood of American Association of Deanna Borrelli Mary Cunneen Brian Fey 12 Miltenyi Biotec Pate and Bill Mears3 Vicinity L.I.U.N.A. Electrical Workers Colleges of Pharmacy Megan Boulette Marla and Ken Cutler Scott Z. Fields, MD1 Mirati Therapeutics Charles Marks and Gladys Monroy3 Laborers International Union of N.A.-Local 332 Stephanie and Michael Jeitner American Association of Immunologists Conor Bourque Mandi Da Silva Robert Figlin, M.D., FACP1, 8 National Electrical Contractors Assoc. The Novick Group Connie McAllister Johnson & Johnson Matching Gifts Program American Diabetes Association Briarcliff Congregational Church Daley Family Foundation, a fund of the Olivera J. Finn, PhD1, 8 Penn-Del-Jersey Chapter Parker Institute for Cancer Immunotherapy Moffitt Cancer Center & Research Institute Thomas H. Keating American Lung Association Women’s Society Chester County Community Foundation Julia Fishburn 12 1, 8 Princess Takamatsu Cancer Research Fund Regeneron Pharmaceuticals, Inc. John E. Oxendine, MBA3, 9 Cameron Koch, PhD American Society of Anesthesiologists Bunny and Frank Brodsky Daniel D’Angelo Ruth Fortson6 12 Seattle Genetics Lisa and Stephen Ryan3 John and Veronica Parker L.F. Driscoll Co. American Society of Hematology Kenneth Paul Brumbaugh Gillian Darr Steven Fortuna 12 Servier Sprinkler Fitters Local Union #692 PENTAX Medical A Division of Phyllis and Lawrence Loeb, American Society of Human Genetics Stuart Buchan Nancy E. Davidson, MD, FAACR1, 3, 4, 8 and Joseph F. Fraumeni Jr., MD1, 5 1, 4, 8 Shire Pharmaceuticals Steven Singer Jewelers, Inc. PENTAX of America, Inc. MD, PhD, FAACR American Society of Nephrology Bernard Bunye Thomas W. Kensler, PhD1, 8 Freehouse Fitness Studio 1, 13 Sidney Kimmel Foundation Ann L. and Daniel D. Von Hoff, Prometheus Laboratories, Inc. Thomas Lynch, MD Tobe Amsterdam Jason Burgess Paul J. Davis, MD1 Karen and Eric Frieman 7, 12 1, 3, 8 1, 8 Taiho Oncology, Inc. MD, FAACR1, 4, 8, 9, 12 Prostate Cancer Foundation Marlene and Laurence J. Marton, MD Karen H. Antman, MD Drs. Jared Hossack and Kelly Burkert James Davis Full Time Practical Nursing Students TESARO, Inc. Pyramid Hotel Group Newmark and Company Real Estate Inc. Jenifer Antonacci California Community Foundation Jerry Delaney Matthew Funk10 7, 12 1, 8 Theradex Systems CHALLENGERS ($5,000 TO $9,999) Victoria M. Richon, PhD1, 8 William Pao, PhD, MD Marina Archangeli California Life Sciences Association (CLSA) DeMasi Stephen Gambino AACR Philadelphia Marathon Rothman Orthopaedics Elizabeth T. Peabody Ryan Archer Kelly Capizzi George Demetri, MD1, 8 Myles Brown, MD1, 13 and LEADERSHIP CIRCLE AdvaMedDx Società Italiana di Cancerologia PNC Financial Services Group, Inc. Association of American Cancer Institutes Allan Caplan Ilene Dickinson Judy E. Garber, MD, MPH, FAACR1, 3, 4, 8 1, 8 INVESTIGATORS ($10,000 TO $24,999) Dana T. Aftab, PhD Steamfitters Local Union 420 Paul and Wendy Rosen Association of American Universities Michael A. Carducci, MD1, 8 Karen Dieckhoff Patricia Gdowik 1 3, 9 1, 8 Padmanee Sharma, MD, PhD , and Stuart and Beverly Aisenbrey TD Bank Mace L. Rothenberg, MD Kelle Atteberry John M. Carethers, MD1, 13 Brigit Dijkhoff Linda Geisler 1, 4, 13 1 1 James P. Allison, PhD, FAACR American Association of Colleges of Nursing The Leukemia & Lymphoma Society Stephen Rubin, MD Sunil S. Badve, MBBS, MD Peter Carr Ethan Dmitrovsky, MD1, 8 Genomic Health
84 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 85
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 84-85 6/3/19 11:31 AM AACR FOUNDATION
Ed Gieselman Louis L. Horton Erica King Robert Loughrin Vernetta J. Mitchell6, 10 and Pharmaceutical Research and Robert Schamis Debra DeGrazia and Dr. William Sun Tona M. Gilmer, PhD1, 8 Allan Horwitz and Linda Harley Janet Klein Jennifer Low, MD, PhD1, 13 Steve Cholewiak Manufacturers of America Kevin Schneider Howard Teicher Hannah Gilmore Cathy Hossack and David Rosenthal Robert Klepacki Casey Luddy MJA Group, LLC Ken Pheasey Mark Schoneveld The Edwin D. Hill Charitable Trust Leslie I. Gold, PhD1, 8, 9 Patricia Hu, Ryan and Roderick Lee Christopher Knight Jackie Lutz Timothy A. Moore Philadelphia Runner Christian Schramm The Philadelphia Affiliate of Susan and Sherwood “Woody” Goldberg Maggie Fabrizio and Joseph Hughes, PhD Nancy E. Kohl, PhD1, 8 Nicole and Gary H. Lyman, PhD1, 8 John Wahl and Harriet Morgan PHL Life Sciences Lauren Schwartz Susan G. Komen for the Cure Michael Goldberg Rod A. Humerickhouse, MD, PhD1 Colleen Kohm M. Gitlin Co. Inc Brooke Morgan William Pizor Marilyn and Alan Schwedel Josie Tomaino Ida Moses Goldstein and Isadore Senderoff James Hutchinson Richard D. Kolodner, PhD, FAACR1, 4, 8 Sarah Mallon Happy Michelle Morgan The NC Pomrehn Family Anna Scott Bell Dorothea Touris Joyce Golic Wen-Jen Hwu, MD, PhD1, 3, 13 Crystal Kraft6 Drew Manalo-LaManna Chase Morgan Pond Lehocky Stern Giordano, LLP Kathleen W. Scotto, PhD1, 8 Kevin Tran Sonia Gonzalez Keithley Hydrocephalus Association Sandy and Bernie Krouse Daneen Marchiano Loraine Ballard Morrill Yashodhar Punati Becky Scull Transportation Management Services Marilyn B. Hirsch and I.U.E.C. Local 5 Leila Kulaib Elaine R. Mardis, PhD1, 2 Michael Mountain Susan and Kanti Rai, MBBS, MD1 Melvin R. Seligsohn Danielle Triplett6 Gary B. Gordon, MD, PhD1, 8 Intech Construction Michelle Joy Kuner Joshua Marley Magdalena Mozga Emma Rando Carla Setzler Melissa Tucci Jack Gorman Irving S. & Alwyn N. Johnson Family Deborah Kusaka Lawrence J. Marnett, DPhil1, 8 Jennifer Murphy Gerald Regni, Jr. Prerak And Salina Shah Turn Key Events, LLC Maria Grasso Foundation, Inc. Jack Kutney Mass Mutual - Greater Philadelphia Caterina Musetti Mark Reid Joan Rankin Shapiro, MD1, 8, 9 David Tuveson, PhD, MD1, 2, 13 Greater Philadelphia Chamber of Commerce IUPAT District Council 21 Laborers’ Local Union 57 Katelyn Masse National Alliance for Eye and Lauren Reiss CCS Associates, Inc.1, 13 United Way California Capital Region Greater Springfield Credit Union Daniel Iwamaye Ellen Lacy James Maxwell Vision Research Elizabeth Reenie Linda and Robert Silverberg United Way of Central New Mexico Robyn and Scott Greenberg Stephanie Jack Lee Lai Jordan McBride Benjamin G. Neel, PhD, MD1, 8 Research!America Sheila and Edward Singer, MD United Way of San Diego County Kelly Griffin Jack Duggans PHC, Inc. Luke K.T. Lam, PhD1, 8 Dan McCallum Joyce Neff Antoni Ribas, PhD, MD1, 2, 13 Susan and William Sisco Unity Electric LLC Elizabeth A. Grimm, PhD1, 8 Jackson White Curt Lampe George McCourt Newman & Co. Sarah Ribner Lillian L. Siu, MD1, 2, 13 University of Kansas Cancer Center Thomas Grone Elizabeth M. Jaffee, MD, FAACR1, 2, 3, 4, 13 Ronald Laskodi Renee McCully Mark and Beth Nicholas Hector Rivera Lisa Sklar Angela Urban Radhika Gunasekera Simone S. Jeffers6 Lauren’s Legacy David B. McFadden, MS1 Darby Nickless Claire Rock Josalyn Slavonic Chris and Dominic Vallone Dhanushka Gunasekera Larry Jenkins Kristin Lawhorne Shane McFadden Nina Becka Ewing’s Sarcoma Foundation Russell Rockwell Amelia Snow Gia Vecchio Christopher Halbrook Jennings Sigmond, P.C. Michelle Le Beau, PhD1, 13 Brad and Maura McIlvain Kevin Noonan, PhD1, 8 Veronica Rodriguez-Bravo, PhD1 Martha Snyder Victor Velculescu, MD, PhD1 Patricia and John Hamer Steven Johnsen, PhD1 Keith Leaphart James Mckeone Nancy Ann Nye-Grindey Ben Roessle Taylor Soltys Barbara Parker-Wahl, MD, and Gregory Harding Peter A. Jones, DSc, PhD, FAACR1, 4, 8 Kelley Lear McKesson Ellen C. O’Connell Robert Rogers Ryan Spack Geoffrey Wahl, PhD, FAACR1, 3, 4, 8 Kevin Heck Carl H. June, MD, FAACR1, 2, 4 Holly LeBihan Mary Nelle McLennan Maureen O’Connor Craig Rogerson Jim Speer Thomas Walsh Emily Heckman JVN Communications, Inc. Leslie LeCount Rodney A. McLeod, Jr. Olufunmilayo I. Olopade, MD, FAACR1, 4, 8 Harvey Rose Joe and Belinda Spina Emily Wards Rocky and Jerry Heller Steven B. Kanner, PhD1 Nancy and Chris Lee Emily McQueen Karen Olsen6 Michael and Gail Rosen Alexis Sprecher Jannet L. Preti and Sheryl A. Warner Lee J. Helman, MD1, 8 Judith E. Karp, MD1 Elizabeth and John Leonard, PhD1, 3, 8, 12 Mechanical Trades Council of Emily O’Malley Nicole Rothberg St. Baldrick’s Foundation Rowan Watson Eileen C. Helzner, MD Dr. and Mrs. Michael Kastan, Krista Lesnewich Delaware Valley Martha Darling and Warren C. and Joy K. Rouse Family Gift Trust John St. Omer Dan Weber Chuck Craft and Mary Hendrix, PhD1, 8 MD, PhD, FAACR1, 4, 8 Maggie Levicoff Nancy and Greg Melara Gilbert S. Omenn, MD, PhD1, 9, 13 Mary Lynne and Raymond Ruddon, Stanbridge Family Charitable Fund at Louis M. Weiner, MD1, 8 Richard W. Hevner Suresh Katakkar Matteo Levisetti, MD1 Jaclyn Mele C. Kent Osborne, MD1, 8 MD, PhD (hc)1, 8 Schwab Charitable/Eric Stanbridge, PhD1, 8 Janna and Brent Weinerman Brittany Heyne Luna Kaufman Tiffany Lewis Merck Foundation Karina Ostien Bruce Ruggeri, PhD1, 8 Samantha Starke Ellen Vicky Weisberg David D. Hickey Judith S. Kaur, MD1, 13 Carol and Rafael Lissack Mes, Inc Tiffany Palenscar Anil K. Rustgi, MD1, 3, 13 Elizabeth Steele The Weller Family Hilton Sales Worldwide Amy Kavanaugh Dalia Littman Helen Metcalf, PhD David R. Parkinson, MD1, 8 John Ryland John Stevens, MD1, 8 Wells Fargo Alex Hohmann Michael Kelley Edison T. Liu, MD1, 2, 13 Susan Meurling John Pasquarella Daniel Sack Cathy and Mike Stewart, MBA6 Vanessa Wheeler Robert Hoiser Kelly Golat Melanoma Research & Michele Loeper Michael L. Meyers, MD, PhD1, 13 Luciano Passador, PhD1 Michele and Howard Sands, PhD1, 8 Paul Stierer Donald Corey Williams Holman Enterprises Scholarship Fund Eileen Loftus6 Millennium 3 Management, Inc. Salvatore Patti Brian Santangelo Sheri and Mitch Stoller6 Yvonne Winig and David Silverstein Esq. Chris Hook Joseph Kestenbaum Elisa Logush Emily Miller Pennsylvania AFL-CIO Charles Santangelo Li-Kuo Su, PhD1, 13 Maureen Winigrad William Horn, MD Sara Kijak Francesca LoPresti David Minor Nancy and Robert Perry Ron Scalzo Mark Sullivan Debra Winter
86 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 87
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 86-87 6/3/19 11:31 AM AACR FOUNDATION
Owen N. Witte, MD, FAACR1, 4, 8 Merck & Co., Inc. John and Elizabeth Leonard Family Foundation Novocure Sarah and Daniel J. Keating, III Rebecca Adelman* Lester Family Foundation engages industry partners in the AACR’s Peter and Claire Wolf Neuroendocrine Tumor Research National Brain Tumor Society William H. Prusoff Foundation Prakash M. Kinthada, PhD Apollo Hospital Systems Daisy Lundsten* mission-based activities year-round. Michael Wortley Foundation7 NeoPharm, Inc. Rivkin Center for Ovarian Cancer Irene D. Pritzker Beverly3 and Stuart Aisenbrey William L. Maness* Kazimierz Wrzeszczynski, PhD1 Novartis7 Ocular Melanoma Foundation Raymond and Beverly Sackler Fund for the Kirin Brewery Co. Ltd. Floyd F. Allen* Heidi and Gary Miller, MD, PhD*1 LEADERSHIP: $100,000 DeeAnn Yabusaki, MA1 Ortho Biotech, Inc. Pharmacyclics, LLC7 Arts and Sciences Maverick Capital Charles Herman Armstrong* Edwin Mirand, DSc, PhD*1, 5 Amgen, Inc. Levent Yarar Pancreatic Cancer Action Network Princess Takamatsu Cancer Research Fund Searle Merrimack Pharmaceuticals Thomas J. Bardos, PhD*1 Evelyn L. Mulligan* AstraZeneca Robert C. Young, MD1, 8 Pfizer Oncology7 Puma Biotechnology, Inc. Seattle Genetics Michael’s Mission Dorothy Bartholomew* Marion A. Nichol* Bayer Healthcare, LLC Dr. Stuart H. and Eleanor H. Yuspa Prevent Cancer Foundation Rosenthal Family Foundation George Sehl, DO Miltenyi Biotec Estate of Charles Bath* William Noble Boehringer Ingelheim Charitable Fund1, 8 SANOFI GENZYME7 Schering-Plough Corp. Servier National Institutes of Health Janel Becker* Gilbert S. Omenn, MD, PhD1 and Bristol-Myers Squibb Zavino Susan G. Komen SuperGen, Inc. Sidney Kimmel Cancer Center New York Community Trust June Biedler, PhD*1 Martha A. Darling Genentech, a member of the Roche Group Renee Zengel-Moore Takeda Oncology7 Taiho Oncology, Inc.7 Ellen V. Sigal, PhD1, 3 Pharmion Corp. The Bosarge Family Foundation John Oxendine, MBA3 Merck & Co., Inc. Bruce Zetter, PhD1, 13 Teva Pharmaceutical Industries, Ltd. Ann L. and Daniel D. Von Hoff, Prostate Cancer Foundation Estate of Eileen C. Brown* The Park Foundation Novocure Lisbeth Zimmerman THE MEDALED SOCIETY: Theradex Oncology7 MD, FAACR1, 4 SLACK Incorporated Joseph H. Burchenal, MD* Arnold E. Reif, DSc1, 5 Pfizer, Inc. AACR FOUNDATION DONORS WHOSE Takeda Oncology, Inc. CUMULATIVE (LIFETIME) GIVING TOTALS Irving Weinstein Foundation The QuadW Foundation and the QuadW Wilfred Sloane Foundation Jennie M. Commisa* Dorothy E. Rose* AACR FOUNDATION GIVING $50,000 TO $999,999 Fund of Communities Foundation of Texas Duk Young Cho Calista I. Salmon* SILVER: CUMULATIVE GIFTS OF $100,000 1 STRATEGIC: $70,000 SOCIETIES PLATINUM: CUMULATIVE GIFTS OF Wyeth Pharmaceuticals DR. BAYARD D. CLARKSON Hugh J. Creech, PhD* Arthur B. Schaefer* TO $249,999 1907 AACR FOUNDERS SOCIETY: $500,000 TO $999,999 LEGACY SOCIETY Mary Jean Dresie* Henry William Schkade, Jr. Incyte Corporation A*STAR AACR FOUNDATION DONORS WHOSE Abbott Laboratories BRONZE: CUMULATIVE GIFTS OF $50,000 Constance Dufour* Joan Rankin Shapiro, MD1, 8 Pharmacyclics, LLC CUMULATIVE (LIFETIME) GIVING EXCEEDS Affymetrix, Inc. TO $99,999 We gratefully acknowledge the following Anonymous in Honor of Dharma Jeannette C. Ford* Gladys M. Sinicrope* $1,000,000 American Cancer Society Abbott Fund individuals who have made an endowed, Master Jiantai Estate of Helen Greenberg* Rose A. Sinkin* MAJOR: $40,000 AbbVie, Inc. AntiCancer, Inc. Abraxis BioScience, Inc. estate, or other planned gift to the American Barletta Foundation Leslie I. Gold, PhD1, 8 Sidney Kimmel Foundation Astex Pharmaceuticals Aflac7 Ash Stevens/Piramal Pharma Solutions American Society of Hematology Association for Cancer Research. Creative Debbie’s Dream Foundation Jean M. Gudas*1, 8 Gerda Sitko* Celgene Corporation Amgen, Inc.7 Astex Pharmaceuticals7 AVEO Pharmaceuticals, Inc. gift planning provides an opportunity to Eisai Co., Ltd.7 Iva Pauline Hancock* Clara Joann Smith* Eisai Co., Ltd. Astellas Pharma US, Inc. Banyu Pharmaceutical Co., Ltd. BD make a meaningful commitment, maximize Gilead Sciences, Inc.7 Gloria W. Heath* Chester Stock, PhD*1 Fondazione Pezcoller AstraZeneca7 Berlex Biosciences Biogen philanthropic objectives, and receive ITO EN, Ltd. Hanwha Holdings (USA) Inc. Eleanor Tepfer* Gilead Sciences, Inc. Avon Foundation for Women Cancer Research Institute BTG International, Inc. important tax benefits. National Foundation for Cancer Research James F. Holland*1, 2, 4, 5 Charles Troester* GlaxoSmithKline Bayer7 Cardinal Health Foundation Clovis Oncology, Inc. OSI Pharmaceuticals, LLC Mihwa and Waun Ki Hong, MD*1, 4 Joseph J. Vita* Janssen Research & Development, LLC Boehringer Ingelheim7 Charles River Laboratories International, Inc. Constellation Wines U.S. All those who have established an estate Pezcoller Foundation Burton Hong and Audrey Cheng Daniel D. Von Hoff, MD, FAACR1, 4, 8 Lilly Oncology Breast Cancer Research Foundation Chiron Corporation EMD Serono, Inc. or other planned gift to the AACR, such Novartis Pharmaceuticals Corporation 7 Triple Negative Breast Cancer Foundation Funan Hsu* Estelle Wals* Bristol-Myers Squibb Suk Rai Cho Exelixis, Inc. as a bequest naming the AACR in their SANOFI GENZYME 7 1, 3, 8 Hyosung USA, Inc. Betty Jean Warner* Celgene Corporation GOLD: CUMULATIVE GIFTS OF $250,000 Conquer Cancer Foundation Margaret Foti, PhD, MD (hc) will, are recognized with membership in Lee J. and Eleonore H. Hymel Charitable Rosemary Weiss* Servier Laboratories Entertainment Industry Foundation TO $499,999 Daiichi Sankyo, Inc. Friends of Cancer Research the Dr. Bayard D. Clarkson Legacy Society. Remainder Trust Lavetta D. Wimmer* Taiho Oncology, Inc. Genentech, a member of The Roche Group7 Agilent Technologies, Inc. IBEW Local Union 98 Gerson Lehrman Group This society honors individuals who have Henrietta Kellems* Theradex Oncology, Inc. GlaxoSmithKline7 American Society of Clinical Oncology Illumina, Inc. Get Your Rear In Gear Philadelphia, invested in sustaining the future of the Vera M. Kirkland* AACR SUSTAINING Incyte Corporation7 W.E. Bosarge, Jr., PhD Kohlberg Foundation supported by the Colon Cancer Coalition AACR and its initiatives so that generations Barbara Kirsh MEMBERSHIP ASSOCIATE Janssen Research & Development, LLC7 Virginia and Bayard D. Clarkson, Loxo Oncology Independent Charities of America to come may benefit from the leadership George A. Koberstein* Asana Biosciences Kirk A. and Dorothy P. Landon Foundation MD, FAACR1, 3, 4 Lustgarten Foundation Johns Hopkins Sidney Kimmel and groundbreaking work of the AACR and The AACR Sustaining Membership Eleanor Kress3 Kure It Cancer Research Fight Colorectal Cancer The Mark Foundation for Cancer Research Comprehensive Cancer Center its membership. Program is a support mechanism that Kun-Hee Lee Lilly Oncology7 Mihwa and Waun Ki Hong, MD, FAACR*1, 4, 9 National Cancer Institute V. Craig Jordan, OBE, PhD, FAACR1, 3, 4
88 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 89
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 88-89 6/3/19 11:31 AM FINANCIAL STATEMENT FINANCIAL
American Association for Cancer Research, Inc. and AACR Foundation UNRESTRICTED REVENUES AND EXPENSES (UNAUDITED) STATEMENT AS OF DECEMBER 31, 2018 2017 2018 2018 PERCENT 2018 TOTAL EXPENSES OF TOTAL REVENUE In 2018, the AACR reported another AACR’s investment portfolio, the portfolio Membership Dues $4,145,566 $4,296,301 4% year of positive operating returns. This experienced negative returns in the amount Fundraising/ Administration 7% Development 5% Scientific Publishing $17,920,478 $20,255,103 18% financial stability enables the AACR to of $5.8 million in 2018 due to a market Scientific Meetings / ducationalE Workshops $23,648,781 $25,714,086 23% comprehensively meet the challenges of the correction. These returns were offset in part Other Revenue $2,669,170 $2,232,813 2%
cancer problem. Operating revenues totaled by the net operating surplus, resulting in Subtotal: Program Revenue $48,383,995 $51,903,543 47% $111.5 million and total expenditures an overall net deficit of $4.4 million for the closely matched revenues. The net impact year. Fortunately, the AACR was able to Support Program of revenues and expenses resulted in an manage its operating budget without using NIH Grants $911,665 $940,501 1% Services Contributions $63,675,776 $58,670,725 52% operating surplus of $1.4 million. As investment income, so the negative market 88% Subtotal: Support Revenue $64,587,441 $52,498,303 53% outlined in this report, several major returns did not have an adverse effect on projects were launched in 2018, and the net operating income. TOTAL REVENUE $112,971,436 $112,109,529 100% AACR was able to outperform the budget through successful programming, revenue As a result of the financial performance for EXPENSES growth, and prudent financial management. the year 2018, the AACR’s unrestricted net Research Grants / Scientific Awards $54,556,901 $51,391,700 47% assets are now $71.8 million. These reserves Scientific Meetings / Educational Workshops $18,110,349 $19,721,140 18% Non-operating activities are primarily ensure continued investment in the programs Scientific Publishing $11,622,941 $11,880,364 11% related to long-term investments. After and initiatives that support the AACR’s 2018 PROGRAM EXPENSES Communications / Science Policy / Patient Education $8,585,386 $8,657,004 8% several years of positive performance in the mission to prevent and cure all cancers. Professional Education / Scientific Programs $4,464,488 $5,188,363 5% Communication/ Subtotal: Program Expenses $97,340,065 $96,838,571 88% Professional Education/ Science Policy/ Scientific Programs 5% Patient Education 9% Member Services / Support Services $7,152,289 $8,303,701 8% Fundraising / Development $4,646,576 $5,050,547 5% Scientific Subtotal: Support Expenses $11,798,865 $13,354,248 12% Publishing Research 12% TOTAL EXPENSES $109,138,930 $110,192,819 100% Grants/ Scientific Operating Surplus before Investments $3,832,506 $1,916,710 Scientific Awards Meetings/ Investment Income $11,324,081 ($5,865,862) 53% Educational Workshops Change in Unrestricted Net Assets $15,156,587 ($3,949,152) 21% NET ASSETS BEGINNING OF YEAR $60,640,037 $75,796,624
NET ASSETS END OF YEAR $75,796,624 $71,847,472
90 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 91
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 90-91 6/3/19 11:31 AM THE AACR IN 2019: A LOOK AHEAD THE AACR IN 2019: LEADING DISCOVERIES, TARGETING CURES A LOOK AHEAD
AACR programs and targeted drug therapies, surgical oncology, and radiation therapy to discuss the initiatives have fostered current status of and challenges to the collaboration, sparked success of combination cancer therapies. The goal of the summit is to better innovation, and driven understand the science and effectiveness progress against cancer in of combining various modalities and to improve the development of combination the past year. Entering 2019, cancer therapies through scientifically driven clinical trials. the AACR will continue • Convergence Cancer Science. This summit, FUTURE OF CANCER that progress in critical which will convene in the fall of 2019, RESEARCH INNOVATION will bring together experts from different areas, forging international SUMMITS areas of science—including life sciences, alliances and redefining the AACR President (2018-2019) and Fellow of engineering, mathematics, chemistry, and the AACR Academy Elizabeth M. Jaffee, MD physical sciences—to discuss recent and frontiers of cancer science (above), will lead the organization’s efforts emerging technologies and methodologies for the benefit of patients. to explore and advance two critical areas that are uncovering new cancer pathways. of cancer science by serving as the chair of Guided by Dr. Jaffee and cochairs Anna D. two Future of Cancer Research Innovation Barker, PhD, Joe W. Gray, PhD, FAACR, Summits to be launched in 2019: Peter Kuhn, PhD, and Charles Swanton, • Combination Therapies. Convening MD, PhD, the summit participants will in June 2019 under the leadership of work to understand the current activities Dr. Jaffee and cochairs Jennifer Rubin that are uniting experts with multiple areas of expertise to attack the cancer problem, (Opposite page) Klaus Pantel, MD, PhD, Grandis, MD, Albert C. Koong, MD, PhD, presents in the Opening Plenary Session to identify the challenges in integrating Patricia M. LoRusso, DO, and Antoni titled "Advancing Cancer Medicine: Ribas, MD, PhD, this summit will bring convergent disciplines, and to determine From Discovery to Patient Care" at the together leaders in immunotherapy, how the AACR can address these challenges AACR Annual Meeting 2018. in the future.
92 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 93
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 92-93 6/3/19 11:31 AM THE AACR IN 2019: A LOOK AHEAD
CATALYZING COLLABORATION for Pediatric Oncology (SIOPE), the TRANSFORMING records. The conference will also address Meeting sessions with AACR scientist EXPANDING AND TRAINING committee will work to expand the AACR’s will strengthen its focus on several scientific IN PEDIATRIC DRUG platform supports collaborations among POPULATION SCIENCE the use of mobile and social media outreach mentors to learn about the innovative THE CANCER RESEARCH portfolio of educational workshops and priorities in 2019, including basic science, DEVELOPMENT pediatric oncologists and clinicians, for study recruitment and retention, science behind their cancer treatments. WORKFORCE develop new in-person and online training survivorship research, cancer disparities, The AACR advances the frontiers of industry scientists, regulatory bodies, and increasing participation in population opportunities—ensuring that investigators early detection and cancer interception, Advances in cancer science require continuous cancer science by understanding the field, • The AACR special conference on Advances AACR leadership is committed to patients to identify and overcome pediatric studies by responding to changes in the way at all career stages are well equipped to face hematological malignancies, new international collaborations, and international identifying the forces impacting the field, in Pediatric Cancer Research will be sustaining the pipeline of researchers in cancer drug development challenges. populations interact. the challenge of preventing and curing all technologies, and pathology. collaborations require a trusted broker to and taking a leadership role in responding held in Montreal, Quebec, in September. all fields of cancer science and medicine cancers. bring together scientists, clinicians, regulators, to those potential changes. In February Cochaired by David Malkin, MD, of the to meet the needs of cancer patients now In June 2018, ITCC and SIOPE launched EXPANDING With the guidance of the Vision 2020 and patient advocates from around the 2019, in association with its Molecular Hospital for Sick Children in Toronto, the and in the future. The recent decision by a project to reorganize and expand the COLLABORATIONS VISION 2020: FOCUS ON strategic plan and the leadership of its Board world. The AACR is such a broker, and in Epidemiology Working Group (MEG), the conference will address the unique issues the AACR Board of Directors to eliminate ACCELERATE platform beyond Europe, IN CANADA SCIENTIFIC PRIORITIES of Directors, the AACR and its more than 2019 the organization will facilitate several AACR will host a special conference on and challenges in investigating the biologic dues for associate members is expected to strengthening international cooperation 40,000 members will continue to be the collaborations in critical areas required to "Modernizing Population Sciences in the The AACR’s international outreach has basis of childhood cancers and translating markedly increase the number of young In the coming year, the AACR will to improve the global development of new most effective catalyst for the prevention catalyze progress against cancer. Digital Age." included efforts to enhance relationships recent findings into new treatment investigators in the AACR membership, continue to pursue the objectives outlined pediatric oncology drugs. In 2019, the and cures of all cancers. with organizations in Canada. These efforts approaches. providing valuable training and networking in its Vision 2020 strategic plan, which AACR Pediatric Cancer Working Group The ACCELERATE platform is the Chaired by MEG Steering Committee will impact several AACR programs and opportunities to early-career investigators was developed by the Board of Directors (PCWG) will work with ITCC and SIOPE • Th e AACR’s focus on eliminating premier European forum for addressing members Melissa L. Bondy, PhD (above), initiatives in 2019: at a critical point in their careers. and the AACR staff in late 2016 to set a to realize that vision. Chaired by Crystal cancer disparities is shared by the CIHR issues associated with the development of and Peter Kraft, PhD, along with Marc T. course for the organization’s growth and L. Mackall, MD (above left), the PCWG • The Canadian Institutes of Health Institute of Cancer Research (ICR). A innovative anticancer medicines for children Goodman, PhD, and Sophia S. Wang, PhD, As the cancer workforce expands, the impact on cancer research. The strategic will facilitate the coordination of efforts Research (CIHR) will sponsor the representative of the ICR participated and adolescents with cancer. Created in the conference will address the ways in AACR will take steps in 2019 to ensure that priorities established in the plan include a among European and U.S. drug developers, participation of three Canadian in the AACR Cancer Health Disparities 2013 by the European Consortium for which population scientists can transform these scientists and clinicians receive the directive to “identify and foster innovative ensuring that pediatric and adolescent patient advocates in the AACR Think Tank held in October 2018, and the Innovative Therapies for Children with their methodologies to incorporate "big ↔ best possible training with the launch of the science that is of the highest priority and cancer patients around the world benefit Scientist Survivor Program at the 2019 AACR and CIHR-ICR will be exploring Cancer (ITCC) and the European Society data," including data from wearable AACR Education and Training Committee. potential for impact in reducing cancer from advances in drug development. AACR Annual Meeting in Atlanta. These additional opportunities to collaborate on incidence, morbidity, and mortality.” In technologies and electronic medical patient advocates will attend Annual this critical issue in 2019 and beyond. Chaired by President-Elect Elaine R. Mardis, PhD (above), this new standing accordance with this directive, the AACR
94 I American Association for Cancer Research Annual Report 2018 American Association for Cancer Research Annual Report 2018 I 95
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 94-95 6/3/19 11:31 AM 96 I American Association for Cancer Research Annual Report 2018
1810051_AACR2018AnnRepTEXT_11x8.5_4.indd 96-3 6/3/19 11:31 AM